

---

# Programma voorjaarsvergadering 20 en 21 maart 2014

## NH Conference Centre Koningshof Veldhoven

---

### NEDERLANDSE VERENIGING VOOR GASTROENTEROLOGIE

Sectie Gastrointestinale Endoscopie  
Netherlands Society for Parenteral and Enteral Nutrition  
Sectie Neurogastroenterologie en Motiliteit  
Sectie Experimentele Gastroenterologie  
Sectie Gastrointestinale Oncologie  
Sectie Inflammatoire Darmziekten IBD  
DEGH-Meeting  
Sectie Kinder-MDL  
V&VN MDL



### NEDERLANDSE VERENIGING VOOR HEPATOLOGIE



### NEDERLANDSE VERENIGING VOOR GASTROINTESTINALE CHIRURGIE



### NEDERLANDSE VERENIGING VAN MAAG-DARM-LEVERARTSEN



|                                                                            |   |
|----------------------------------------------------------------------------|---|
| Belangrijke mededeling over de aanwezigheid van farmaceutische industrieën | 4 |
| Voorwoord                                                                  | 5 |

### **Woensdag 19 maart 2014**

|                                               |   |
|-----------------------------------------------|---|
| Programma cursorisch onderwijs in MDL-ziekten | 6 |
|-----------------------------------------------|---|

|                                                                            |   |
|----------------------------------------------------------------------------|---|
| <i>Schematisch overzicht van de programma onderdelen op 20 en 21 maart</i> | 7 |
|----------------------------------------------------------------------------|---|

### **Donderdag 20 maart 2014**

|                                                                                    |    |
|------------------------------------------------------------------------------------|----|
| Vrije voordrachten Nederlandse Vereniging voor Gastroenterologie - Brabantzaal     | 10 |
| Vrije voordrachten Sectie Gastrointestinale Oncologie – Brabantzaal                | 12 |
| Vrije voordrachten Nederlandse Vereniging voor Gastroenterologie - Brabantzaal     | 14 |
| Frieda den Hartog Jager prijs, uitreiking en lezing door prof. dr. J.H. Kleibeuker | 16 |
| President Select (plenaire sessie) - Brabantzaal                                   | 16 |
| State of the art lecture prof. dr. E.M. El-Omar - Brabantzaal                      | 17 |
| Vrije voordrachten NVGIC - Auditorium                                              | 18 |
| Symposium NVGIC I ochtendprogramma – Auditorium                                    | 20 |
| Symposium NVGIC II – middagprogramma - Auditorium                                  | 20 |
| Dutch Experimental Gastroenterology and Hepatology Meeting (DEGH)                  | 22 |
| Multidisciplinair Symposium Darmfalen - Parkzaal                                   | 26 |
| Vrije voordrachten Sectie Inflammatoire Darmziekten - Parkzaal                     | 27 |
| Minisymposium: Update Voeding in de dagelijkse praktijk                            | 30 |

### **Tijdstippen diverse ledenvergaderingen tijdens voorjaarsvergadering:**

|                                               |                                   |
|-----------------------------------------------|-----------------------------------|
| Nederlandse Vereniging voor Gastroenterologie | 20 maart, 11.30 uur – Brabantzaal |
| Vergadering Sectie Kinder-MDL                 | 20 maart, 11.30 uur - zaal 81     |
| Ledenvergadering NVMDL i.o.                   | 20 maart, 12.00 uur – zaal 63-64  |
| Nederlandse Vereniging voor Hepatologie       | 20 maart, 15.00 uur – Baroniezaal |

**Vrijdag 21 maart 2014**

|                                                                               |             |
|-------------------------------------------------------------------------------|-------------|
| Vrije voordrachten Sectie Gastrointestinale Endoscopie - Brabantzaal          | 31          |
| Perkstudie - Brabantzaal                                                      | 33          |
| Richtlijn antistolling - Brabantzaal                                          | 33          |
| Symposium CRC Bevolkingsonderzoek - Brabantzaal                               | 34          |
| Vrije voordrachten NVGE-NVGIC - Auditorium                                    | 35          |
| Vrije voordrachten Nederlandse Vereniging voor Gastroenterologie - Auditorium | 36          |
| Vrije voordrachten NVGE-NVGIC - Auditorium                                    | 38          |
| Symposium Nederlandse Vereniging voor Hepatologie - Baroniezaal               | 40          |
| Posterrounds DEGH in de zalen 19 en 20                                        | 41          |
| Dutch Experimental Gastroenterology and Hepatology Meeting (DEGH)             | 45          |
| Vrije voordrachten NVGE en Sectie Inflammatoire Darmziekten - Parkzaal        | 48          |
| Vrije voordrachten Sectie Inflammatoire Darmziekten - Parkzaal                | 49          |
| NESPEN vrije voordrachten                                                     | 52          |
| NESPEN symposium                                                              | 53          |
| Programma V&VN MDL                                                            | 55          |
| <br>Abstracts voorjaarscongres 2014                                           | <br>67      |
| <br>Overzicht aanwezige bedrijven                                             | <br>192     |
| Plattegrond expositie                                                         | 193         |
| Plattegrond Koninghof                                                         | 194         |
| <br><br>Aanmeldingsformulier lidmaatschap NVGE                                | <br><br>195 |
| Aanmeldingsformulier lidmaatschap NVH                                         | 197         |

**Tijdstippen diverse ledenvergaderingen tijdens voorjaarsvergadering:**

|                                                    |                                     |
|----------------------------------------------------|-------------------------------------|
| Nederlandse Vereniging van Maag-Darm-Leverartsen   | 21 maart, 08.00 uur – Zaal 81-82-83 |
| V & VN MDL                                         | 21 maart, 11.45 uur – Beneluxhal    |
| Vergadering Sectie Inflammatoire Darmziekten (IBD) | 21 maart, 13.00 uur – Parkzaal      |

## **Belangrijke mededeling over de aanwezigheid van farmaceutische industrieën**



*Aan alle deelnemers aan de voorjaarsvergadering op 20 en 21 maart 2014*

De Nederlandse Vereniging voor Gastroenterologie kent een jarenlange samenwerking met de farmaceutische industrie. De vereniging stelt de farmaceutische industrie in de gelegenheid aanwezig te zijn bij de wetenschappelijke vergaderingen met een stand. Mede hierdoor kan de vereniging haar wetenschappelijke bijeenkomsten organiseren.

De Geneesmiddelenwet zegt dat - onder strikte voorwaarden - de farmaceutische industrie alleen reclame mag maken voor receptgeneesmiddelen voor personen die bevoegd zijn om dergelijke geneesmiddelen voor te schrijven. Alle andere personen (inclusief bijvoorbeeld verpleegkundigen, endoscopie-assistenten en biochemici) worden beschouwd als “publiek”. De farmaceutische industrie mag geen reclame maken voor receptgeneesmiddelen voor publiek. De Nederlandse Vereniging voor Gastroenterologie is een wetenschappelijke vereniging voor personen die beroepsmatig betrokken zijn bij zorg, onderwijs en onderzoek ten behoeve van patiënten met maag-, darm- en leveraandoeningen. Dat betekent dat ook personen die geen arts zijn, lid van de NVGE zijn. De aanwezigheid van artsen, niet-artsen en farmaceutische industrieën tijdens de voorjaarsvergadering kan de NVGE ongewild in aanraking brengen met de inspectie voor de gezondheidszorg, sectie reclametoezicht, en daarmee in diskrediet worden gebracht. Dat willen wij uiteraard voorkomen.

In verband met de Gedragscode Geneesmiddelenreclame van de CGR en de aan het NVGE-congres verbonden expositie van farmaceutische producten, medische instrumenten en voedingsmiddelen, zal bij uw congresregistratie via de NVGE-website worden gevraagd naar uw bevoegdheid om medicijnen voor te schrijven.

Alle congresdeelnemers dragen verplicht een congresbadge waarop behalve de naam ook beroep/ functie staat aangegeven. Farmaceutische standhouders benaderen uitsluitend congresdeelnemers die de bevoegdheid hebben om receptgeneesmiddelen voor te schrijven of ter hand te stellen. Om dit extra te verduidelijken zal tijdens het voorjaarscongres worden gekozen voor verschillende kleuren congres-badges.

Uit het bovenstaande volgt dat aanwezige reclame-uitingen en merkproductinformatie van farmaceutische industrieën alleen gericht zijn op personen die bevoegd zijn om de betreffende geneesmiddelen voor te schrijven. Wij maken u erop attent dat het voor niet-artsen dan ook niet is toegestaan de stands van de aanwezige farmaceutische industrieën te bezoeken.

De NVGE en farmaceutische industrie (sponsors) vertrouwen erop u met bovenstaande voldoende te hebben geïnformeerd.

Het bestuur van de NVGE

---

## VOORWOORD

---

Hierbij treft u het volledige programma aan van het voorjaarscongres op 20 en 21 maart in NH Conference Center Koningshof te Veldhoven. Zoals gebruikelijk wordt ons congres voorafgegaan door het cursorisch onderwijs op 19 maart, deze keer over oncologie, waarvan u het programma aantreft op bladzijde 6 en 7.

Er is in het voorjaar traditiegetrouw veel ruimte voor voordrachten van wetenschappelijk onderzoek. Dit wordt aangevuld met uiteenlopende symposia, te beginnen met een multidisciplinair symposium over darmfalen op donderdagmorgen.

In de Baroniezaal is zowel op donderdag als op vrijdag de Dutch Experimental Gastroenterology and Hepatology Meeting, een gezamenlijk initiatief van de Sectie Experimentele Gastroenterologie van de NVGE en de Sectie Basale Hepatologie van de NVH. Dit jaar staat dit programma in het teken van *translational medicine*. Onze gastspreker professor E.M. El-Omar – Aberdeen University, UK – zal dit thema ook uiteenzetten in de afsluitende plenaire sessie in de Brabantzaal met een voordracht getiteld *Challenges of Translational GI Research* om 18.00 uur in de Brabantzaal.

Na de lunch is er naast uiteenlopende parallelsessies een symposium van de Nederlandse Vereniging voor Gastrointestinale Chirurgie in het Auditorium en een minisymposium over voeding in de dagelijkse praktijk.

Om 17.00 uur vindt in de Brabantzaal de uitreiking plaats van de Frieda den Hartog Jager Prijs aan professor dr. J.H. Kleibeuker, die aansluitend een ere-voordracht houdt getiteld *Pathogenese en preventie van colorectaal carcinoom: the continuing story*. Om 17.30 uur volgt de President Select, zoals gebruikelijk plenair, met om 18.00 uur de voordracht over translationeel onderzoek van gastspreker professor E.M. El-Omar, editor van GUT.

Op vrijdagochtend is na de ALV van de NVMDL weer veel ruimte voor vrije voordrachten van onder meer de Sectie Gastrointestinale Endoscopie en een klinisch NVH-symposium. Na de koffiepauze wordt in de Brabantzaal gerapporteerd over de resultaten van de PERK-studie met aansluitend aandacht voor de nieuwe richtlijn antistolling. In zaal 80 vindt het NESPEN symposium plaats. Gedurende de gehele vrijdag zijn er genodigde sprekers en vrije voordrachten van de DEGH.

Na de lunch volgt in de Brabantzaal een symposium over poliepen en CRC met het oog op het bevolkingsonderzoek, en wederom abstractsessies van NVGE/NVGIC, NVGE en IBD. In de Beneluxhal wordt door de Verpleegkundigen en Verzorgenden Nederland MDL (V&VN MDL) een eigen programma met lezingen verzorgd, met daarnaast een keuze uit verschillende subsessies.

Kortom, een gevarieerd en inspirerend programma.

Dr. J.J. Keller, secretaris

Dr. K. van der Linde, bestuurslid

**Cursuscommissie**

Prof. dr. P.D. Siersema (voorzitter), MDL-arts, UMC Utrecht  
Mevr. dr. C.M. Bakker, MDL-arts, Atrium MC, Heerlen  
Prof. dr. U.H.W. Beuers, MDL-arts, AMC, Amsterdam  
Drs. M.P.J. van den Broek, AIOS MDL, LUMC, Leiden  
Dr. J. Heisterkamp, chirurg, St. Elisabeth Ziekenhuis, Tilburg  
Mevr. dr. A.M.J. Langers, MDL-arts, LUMC, Leiden  
Drs. M.C.P. Pennings, AIOS MDL, UMC St Radboud, Nijmegen  
Dr. B.J. Veldt, MDL-arts, Reinier de Graaf Gasthuis, Delft  
Dr. J. Vecht, MDL-arts, Isala Klinieken, Zwolle  
Dr. R.A. de Vries, MDL-arts, VUmc, Amsterdam  
Dr. P.J. Wahab, MDL-arts, Rijnstate Ziekenhuis, Arnhem



**Thema: Oncologie**

**Poliepen**

*voorzitters:* U.H.W. Beuers en P.D. Siersema

- |               |                                                                                                                                          |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------|
| 14.15 – 14.30 | Opening en kennistoets                                                                                                                   |
| 14.30 – 14.50 | Niet invasieve CRC screeningstesten<br><i>Dr. K.H.N. de Boer, MDL-arts, VU medisch centrum, Amsterdam</i>                                |
| 14.50 – 15.20 | Hoe verricht ik een goede coloscopie en hoe kan ik mijn poliepdetectie verhogen?<br><i>Prof. dr. E. Dekker, MDL-arts, AMC, Amsterdam</i> |
| 15.20 – 15.40 | Een serrated adenoma! Wat betekent dat eigenlijk?<br><i>Dr. S. Sanduleanu, MDL-arts, MUMC, Maastricht</i>                                |
| 15.40 – 16.00 | Hoe ga ik om met een “grote” ( $\geq 2$ cm) poliep?<br><i>Dr. J. Hardwick, MDL-arts, Leids Universitair Medisch Centrum</i>              |

**Colorectaal carcinoom**

- |               |                                                                                                                                                                   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 16.00 – 16.20 | Wanneer moet ik denken aan een erfelijke darmtumor en wat betekent dat voor de patiënt en de familie?<br><i>Dr. F.M. Nagengast, MDL-arts, Radboudumc Nijmegen</i> |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Woensdag 19 maart 2014

---

| <b>Cursorisch onderwijs in maag-darm-leverziekten</b> | <b>Auditorium</b> |
|-------------------------------------------------------|-------------------|
|-------------------------------------------------------|-------------------|

---

|               |                                                                                                                |
|---------------|----------------------------------------------------------------------------------------------------------------|
| 16.20 – 16.40 | Hoe voorkom ik IBD- en IBD-medicatie gerelateerde carcinomen<br><i>Dr. B. Oldenburg, MDL-arts, UMC Utrecht</i> |
|---------------|----------------------------------------------------------------------------------------------------------------|

|               |       |
|---------------|-------|
| 16.40 – 17.10 | Pauze |
|---------------|-------|

|               |                                                                                                                                                           |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17.10 – 17.40 | Rol van pathologisch onderzoek bij de keuze van chemotherapeutische behandeling van CRC<br><i>Prof. dr. C.J.A. Punt, medisch oncoloog, AMC, Amsterdam</i> |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

|               |                                                                                                                                                                                   |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17.40 – 18.05 | De chirurgische en endoscopische behandeling van CRC en complicaties, en hoe licht ik mijn patiënt voor?<br><i>Dr. W.J.H.J. Meijerink, chirurg, VU medisch centrum, Amsterdam</i> |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

### **Potpourri**

|               |                                                                                                                |
|---------------|----------------------------------------------------------------------------------------------------------------|
| 18.05 – 18.35 | Hobbels en bobbels in het maagdarmkanaal: NET en GIST<br><i>Dr. H.M. van Dullemen, MDL-arts, UMC Groningen</i> |
|---------------|----------------------------------------------------------------------------------------------------------------|

|               |                                                                                                                                          |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------|
| 18.35 – 18.55 | Wat is de rol van de MDL-arts bij lymfomen van het maagdarmkanaal<br><i>Dr. H. Boot, MDL-arts, Antoni van Leeuwenhoekhuis, Amsterdam</i> |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------|

|               |                                                                                                                                           |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| 18.55 – 19.15 | Help, een tumor van het periampullaire gebied: hoe pak ik dat aan als MDL-arts?<br><i>Dr. J.W. Poley, MDL-arts, Erasmus MC, Rotterdam</i> |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------|

|       |                 |
|-------|-----------------|
| 19.15 | Einde programma |
|-------|-----------------|

|               |       |
|---------------|-------|
| 19.15 – 20.45 | Diner |
|---------------|-------|

*De cursuscommissie verwacht van de MDL-artsen i.o. dat ze de Cursus Klinische Hepatologie(NVH) tijdens de Dutch Liver Week éénmaal bezoeken in het tweede deel van de MDL-opleiding (jaar vier tot zes).*

Op het cursorisch onderwijs zijn conform de eisen van het Centraal Register Kort Beroepsonderwijs leveringsvoorwaarden van toepassing. Informatie vindt u op de onderwijspagina van [www.mdl.nl](http://www.mdl.nl) en [www.nvge.nl](http://www.nvge.nl).

## Programma donderdag 20 maart 2014

| Donderdag     | Brabantzaal                                                                            | Baroniezaal                                       | Auditorium                                                                                                  | Parkzaal                                                               |
|---------------|----------------------------------------------------------------------------------------|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| 09.00         | Ontvangst en koffie                                                                    | Ontvangst en koffie                               | Vrije voordrachten Ned. Vereniging voor Gastrointestinale Chirurgie (aanvang 09.30)                         | Ontvangst en koffie                                                    |
| 10.00 - 11.30 | Vrije voordrachten Ned. Vereniging voor Gastro-enterologie<br>pagina 10                | DEGH-meeting (aanvang 10.30 uur)<br><br>pagina 22 | pagina 18                                                                                                   | Multidisciplinair symposium Darmfalen (aanvang 09.30)<br><br>pagina 26 |
| 11.30 - 12.00 | Ledenvergadering NVGE                                                                  |                                                   | Geen programma i.v.m. Ledenvergadering NVGE                                                                 | Geen programma i.v.m. Ledenvergadering NVGE                            |
| 12.00 - 13.00 | Lunch in expositiehal                                                                  | Lunch in expositiehal                             | Lunch in expositiehal                                                                                       | Lunch in expositiehal                                                  |
| 13.00 – 15.00 | Vrije voordrachten sectie Gastrointestinale Oncologie<br>pagina 12                     | DEGH-meeting<br>pagina 23                         | Symposium NVGIC: 'Van anussparende chirurgie tot rectumsparende endoscopie'<br><br>pagina 20                | Vrije voordrachten sectie Inflammatoire Darmziekten<br>pagina 27       |
| 15.00 - 15.30 | Theepauze                                                                              | Theepauze + ALV NVH                               | Theepauze                                                                                                   | Theepauze                                                              |
| 15.30 - 17.00 | Vrije voordrachten Nederlandse Vereniging voor Gastroenterologie<br>pagina 14          | DEGH-meeting<br>pagina 24                         | Symposium NVGIC: 'Uitkomsten en transparantie van de colorectale diagnostiek en chirurgie'<br><br>pagina 20 | Minisymposium: 'Update Voeding in de dagelijkse praktijk'<br>pagina 30 |
| 17.00 - 17.30 | Uitreiking Frieda den Hartog-Jager Prijs aan prof. dr. J.H. Kleibeuker<br>pagina 16    |                                                   |                                                                                                             |                                                                        |
| 17.30 - 18.00 | President Select<br>pagina 16                                                          |                                                   |                                                                                                             |                                                                        |
| 18.00 – 18.30 | State of the art lecture Professor E.M. El-Omar – Aberdeen University, UK<br>pagina 17 |                                                   |                                                                                                             |                                                                        |
| 18.30 - 19.30 | Borrel in expositiehal                                                                 |                                                   |                                                                                                             |                                                                        |
| 19.30 - 22.00 | Diner Genderzaal                                                                       |                                                   |                                                                                                             |                                                                        |
| 22.00 - 01.00 | Borrel / Muziek in foyer                                                               |                                                   |                                                                                                             |                                                                        |

## Vrijdag 21 maart 2014

| Vrijdag       | Brabantzaal                                                               | Baroniezaal                                                                             | Auditorium                                                                                                      | Parkzaal                                                                                                               |
|---------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| 08.30         |                                                                           | Posterrondes zaal 19 en 20<br>(aanvang 09.00)                                           |                                                                                                                 |                                                                                                                        |
| 09.30 – 11.00 | Vrije voordrachten sectie<br>Gastrointestinale<br>Endoscopie<br>pagina 31 | Symposium Ned.<br>Vereniging voor<br>Hepatology<br>pagina 40                            | Vrije voordrachten Ned.<br>Vereniging voor<br>Gastroenterologie en<br>Gastrointestinale<br>pagina 35            | Vrije voordrachten Ned.<br>Vereniging voor<br>Gastroenterologie en<br>sectie Inflammatoire<br>Darmziekten<br>pagina 48 |
| 11.00 - 11.30 | Koffiepauze                                                               | Koffiepauze                                                                             | Koffiepauze                                                                                                     | Koffiepauze                                                                                                            |
| 11.30 - 13.00 | Symposium<br>PERK studie en<br>Richtlijn Antistolling<br>pagina 33        | DEGH-meeting<br>pagina 45                                                               | Vrije voordrachten Ned.<br>Vereniging voor<br>Gastroenterologie<br>pagina 36                                    | Vrije voordrachten<br>Sectie Inflammatoire<br>Darmziekten<br>pagina 49                                                 |
| 13.00 – 14.00 | Lunch expositiehal                                                        | Lunch expositiehal                                                                      | Lunch expositiehal                                                                                              | Lunch expositiehal                                                                                                     |
| 14.00 – 15.30 | Symposium: CRC<br>Bevolkingsonderzoek<br>pagina 34                        | DEGH-meeting<br>pagina 45<br><br>Abstract and Poster<br>Prizes and goodbye<br>pagina 47 | Vrije voordrachten Ned.<br>Vereniging voor<br>Gastroenterologie en<br>Gastrointestinale<br>Chirurgie -pagina 48 | Geen programma in<br>deze zaal in de middag                                                                            |
| 15.30 – 16.00 | Afsluiting in expositiehal                                                |                                                                                         | Afsluiting in expositiehal                                                                                      |                                                                                                                        |

## Vrijdag 21 maart 2014 - programma V&VN MDL en NESPEN

| Vrijdag       | Beneluxhal                                                         | Zaal 63                                                               | Zaal 64                                                                 | Zaal 80                                                                                                        |
|---------------|--------------------------------------------------------------------|-----------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| 10.00 – 12.15 | Plenair ochtendprogramma<br>V&VN MDL<br>pagina 55                  |                                                                       |                                                                         | Voordrachten<br>NESPEN, om 10.00.<br>gevolgd door<br>Symposium 'klinisch<br>voedingsonderzoek'<br>pagina 52-53 |
| 12.15         | Lunch in expo                                                      |                                                                       |                                                                         | Lunchbuffet 13.30                                                                                              |
| 13.45 – 15.15 | Parallel programma<br>Endoscopie-<br>verpleegkundigen<br>pagina 55 | Parallel programma<br>Lever- en IBD-<br>verpleegkundigen<br>pagina 56 | Parallel programma<br>Voedingsverpleeg-<br>kundigen en MDL<br>pagina 56 | Geen programma in<br>deze zaal in de middag                                                                    |
| 15.15         | Einde programma                                                    | Einde programma                                                       | Einde programma                                                         |                                                                                                                |

Donderdag 20 maart 2014

---

**Voordrachten Nederlandse Vereniging voor Gastroenterologie**

**Brabantzaal**

---

**Voorzitters:** E.J. Schoon en V.M.C.W. Spaander

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

- 10.00      Introductie voorzitter(s) op het programma
- 10.10      Cost effectiveness of Barrett's esophagus surveillance in a prospective followed cohort in the Netherlands (p. 57)  
*S.H. van Olphen<sup>1</sup>, F. Kastelein<sup>1</sup>, E.W. Steyerberg<sup>2</sup>, C.W.N. Looman<sup>2</sup>, M.C.W. Spaander<sup>1</sup>, M.J. Bruno<sup>1</sup>, E.W. Bekker Grob<sup>2</sup> on behalf of the ProBar study group, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, The Netherlands, <sup>2</sup>Dept of Public Health, Erasmus University Medical Center Rotterdam, The Netherlands*
- 10.20      Does use of NSAIDs, statins and proton pump inhibitors prevent development of esophageal adenocarcinoma among patients with Barrett's esophagus? Results from a multinational population based case control study (p. 58)  
*G.M.C. Masclee<sup>1,2</sup>, P.M. Coloma<sup>1</sup>, E.J. Kuipers<sup>2</sup>, M.C.J.M. Sturkenboom<sup>1,3</sup>, <sup>1</sup>Dept of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands, <sup>2</sup>Dept of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands, <sup>3</sup>Dept of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.*
- 10.30      FISH Biomarkers for the Detection of Dysplasia and Prediction of Malignant Progression in Non dysplastic Barrett's Esophagus (p. 59)  
*M.R. Timmer<sup>1, 2</sup>; C.T.I. Lau<sup>2</sup>; W. Rosmolen<sup>1</sup>; S.L. Meijer<sup>3</sup>; M.G.W. Dijkgraaf<sup>4</sup>; R.C. Mallant Hent<sup>5</sup>; A.H. Naber<sup>6</sup>; A.H. van Oijen<sup>7</sup>; L.C. Baak<sup>8</sup>; P. Scholten<sup>9</sup>; C. Böhmer<sup>10</sup>; P. Fockens<sup>1</sup>; J.J. Bergman<sup>1</sup>; K.K. Krishnadath<sup>1,2</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, <sup>3</sup>Dept of Pathology, Academic Medical Center, Amsterdam, Netherlands. <sup>4</sup>Clinical Research Unit, Academic Medical Center, Amsterdam, <sup>5</sup>Dept. of Gastroenterology, Flevoziekenhuis, Almere, Netherlands. <sup>6</sup>Dept. of Gastroenterology, Tergooiziekenhuizen, Hilversum, <sup>7</sup>Dept. of Gastroenterology, Medisch Centrum Alkmaar, Alkmaar, <sup>8</sup>Dept. of Gastroenterology, Onze Lieve Vrouwe Gasthuis, Amsterdam, <sup>9</sup>Dept. of Gastroenterology, Sint Lucas Andreas Ziekenhuis, Amsterdam, Netherlands. <sup>10</sup>Dept. of Gastroenterology, Spaarneziekenhuis, Hoofddorp, Netherlands.*
- 10.40      SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus (p. 60)  
*S.H. van Olphen<sup>1, 2</sup>, K. Biermann<sup>2</sup>, F. Kastelein<sup>1</sup>, B.E. Hansen<sup>1</sup>, H.A. Stoop<sup>2</sup>, M.C.W. Spaander<sup>1</sup>, L.H.J. Looijenga<sup>2</sup>, M.J. Bruno<sup>1</sup> on behalf of the ProBar study group, <sup>1</sup> Dept of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, The Netherlands, <sup>2</sup>Dept of Pathology, Erasmus University Medical Center Rotterdam, The Netherlands*

- 10.50      The influence of prophylactic proton pump inhibitor treatment on the development of symptomatic marginal ulceration: a historic cohort study (p. 61)  
*U.K. Coblijn<sup>1</sup>, S.M.M. de Castro<sup>1</sup>, S.M. Lagarde<sup>2</sup>, S.D. Kuiken<sup>3</sup>, B.A. van Wagenveld<sup>1</sup>, <sup>1</sup>Sint Lucas Andreas Ziekenhuis, Dept of General Surgery, <sup>2</sup>Academic Medical Center Amsterdam, Dept of General Surgery, <sup>3</sup>Sint Lucas Andreas Ziekenhuis, Dept of Gastroenterology*
- 11.00      **MLDS voordracht**  
A prospective study on intake of meat and heme iron, nitrite, nitrate and nitrosamines as risk factors for adenocarcinoma of esophagus (EAC) and gastric cardia (GCA), esophageal squamous cell carcinoma (ESCC), and Barrett's esophagus (BE) (p. 62)  
*P.A. van den Brandt<sup>1</sup>, A.P. Keszei<sup>1</sup>, A.L.C. Driessen<sup>2</sup>, C.J.R. Huysentruyt<sup>2</sup>, Y.C.A. Keulemans<sup>3</sup>, R.A. Goldbohm<sup>4</sup>, L.J. Schouten<sup>1</sup>, <sup>1</sup>School for Oncology and Developmental Biology (Grow), Dept of Epidemiology, Maastricht University, Maastricht, the Netherlands <sup>2</sup>School for Oncology and Developmental Biology (Grow), Dept of Pathology, Maastricht University, Maastricht, The Netherlands <sup>3</sup>Dept of Gastroenterology, Maastricht University Medical Centre, Maastricht, the Netherlands <sup>4</sup>Dept of Prevention and Health, TNO Quality of Life, Leiden, The Netherlands*
- 11.15      **MLDS voordracht**  
Human buccal epithelium acquires microbial hyporesponsiveness at birth, a role for secretory leukocyte protease inhibitor (p. 63)  
*C.L. Menckeborg<sup>1,8</sup>, J. Hol<sup>1,2,3,8</sup>, L.F. de Ruiter<sup>1,2</sup>, H.C. Raatgeep<sup>1</sup>, Y. Simons Oosterhuis<sup>1</sup>, D. J. Lindenberg Kortleve<sup>1</sup>, A.M. Korteland van Male<sup>1</sup>, S. El Aidy<sup>4</sup>, P.P.E. van Lierop<sup>1</sup>, M. Kleerebezem<sup>4</sup>, M. Groeneweg<sup>5</sup>, G. Kraal<sup>6</sup>, B.E. Elink Schuurman<sup>2</sup>, J.C. de Jongste<sup>2</sup>, E.E.S. Nieuwenhuis<sup>1,7,8</sup>, J.N. Samsom<sup>1,8</sup> <sup>1</sup>Laboratory of Pediatrics, division of Gastroenterology and Nutrition, Erasmus MC, Rotterdam, The Netherlands <sup>2</sup>Dept of Pulmonary diseases, Sophia Children's Hospital, Rotterdam, The Netherlands <sup>3</sup>Dept of Pediatrics, University Hospital Ghent, Ghent, Belgium <sup>4</sup>Laboratory of Microbiology and Host Microbe Interactomics Group, Wageningen University, Wageningen, The Netherlands <sup>5</sup>Maasstad Hospital, Dept of Pediatrics, Rotterdam, The Netherlands <sup>6</sup>Dept of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands <sup>7</sup>Wilhelmina Children's Hospital, Utrecht, The Netherlands <sup>8</sup>Authors have equally contributed*
- 11.30      Korte ledenvergadering Nederlandse Vereniging voor Gastroenterologie
- 12.00      Lunch in expositiehal

Donderdag 20 maart 2014

---

**Vrije voordrachten Sectie Gastrointestinale Oncologie**

**Brabantzaal**

---

**Voorzitters:** G.H. de Groot en K.M.A.J. Tytgat

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

- 13.00      Inleiding op de sessie door de voorzitter
- 13.10      Impact of neoadjuvant chemoradiotherapy on prognostic factors for survival in patients with esophageal or junctional cancer (p. 64)  
*J. Shapiro<sup>1</sup>, H.F. Lingsma<sup>2</sup>, P. van Hagen<sup>1</sup>, A.K. Talsma<sup>1</sup>, B.P.L. Wijnhoven<sup>1</sup>, E.W. Steyerberg<sup>2</sup>, A. van der Gaast<sup>3</sup>, J.J.B. van Lanschot<sup>1</sup>, On behalf of the CROSS Study Group, <sup>1</sup>Dept of Surgery, <sup>2</sup>Dept of Public Health, <sup>3</sup>Dept of Med Oncology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands*
- 13.20      Palliative care of esophageal cancer in the Netherlands: determinants associated with treatment decisions (p. 65)  
*J.L. Opstelten<sup>1</sup>, L.R. de Wijkerslooth<sup>2</sup>, M. Leenders<sup>1</sup>, D.J. Bac<sup>3</sup>, M.A. Brink<sup>2</sup>, B.C.A.J. Loffeld<sup>4</sup>, M.J.F. Meijnen-Bult<sup>5</sup>, I.M. Minderhoud<sup>6</sup>, M.A.M.T. Verhagen<sup>7</sup>, M.G.H. van Oijen<sup>1</sup>, P.D. Siersema<sup>1</sup>, <sup>1</sup>Universit Medical Center Utrecht, Utrecht, <sup>2</sup>Meander Medical Center, Amersfoort, <sup>3</sup>Hospital Gelderse Vallei, Ede, <sup>4</sup>Zuwe Hofpoort Hospital, Woerden, <sup>5</sup>St Jansdal Hospital, Harderwijk, <sup>6</sup>Tergooi Hospitals, Hilversum/Blaricum, <sup>7</sup>Diakonessenhuis, Utrecht/ Zeist, The Netherlands*
- 13.30      GATA6 expression in Barrett's metaplasia development and progression towards malignancy (p. 66)  
*K. Pavlov<sup>1</sup>, H. Judith<sup>2</sup>, C. Meijer<sup>3</sup>, W. Boersma<sup>1</sup>, F.T. Peters<sup>1</sup>, A. van den Berg<sup>4</sup>, A. Karrenbeld<sup>4</sup>, J.T.M. Plukker<sup>2</sup>, F.A.E. Kruijs<sup>3</sup>, J.H. Kleibeuker<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, <sup>2</sup>Dept of Surgical Oncology, <sup>3</sup>Dept of Medical Oncology, <sup>4</sup>Dept of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands*
- 13.40      Clinicopathological characteristics of pancreatic resection specimens of inherited / familial versus sporadic pancreatic ductal adenocarcinoma (p. 67)  
*F. Harinck<sup>1</sup>, F. Boersma<sup>1</sup>, I. Konings<sup>1</sup>, P. Fockens<sup>2</sup>, J.E. van Hooft<sup>2</sup>, M. Dijkgraaf<sup>3</sup>, W.N. Dinjens<sup>4</sup>, K. Biermann<sup>4</sup>, M.J. Bruno<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>2</sup>Dept of Gastroenterology and Hepatology, and <sup>3</sup>Clinical Research Unit, Academic Medical Center, Amsterdam, <sup>4</sup>Dept of Pathology, Erasmus MC, Rotterdam, The Netherlands*
- 13.50      Psychological burden of repeated pancreatic surveillance in high risk individuals for pancreatic cancer (p. 68) *I.C.A.W. Konings<sup>1</sup>, G.N. Sidharta<sup>2</sup>, F. Harinck<sup>1</sup>, C. Aalfs<sup>3</sup>, E. Smets<sup>4</sup>, J.W. Poley<sup>1</sup>, A. Wagner<sup>5</sup>, J.E. van Hooft<sup>6</sup>, A. van Rens<sup>7</sup>, P. Fockens<sup>6</sup>, M.J. Bruno<sup>1</sup>, E.M.A. Bleiker<sup>2,7</sup>, On behalf of the Dutch research group on pancreatic cancer surveillance in high risk individuals, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, <sup>2</sup>Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, <sup>3</sup>Dept of Clinical Genetics, and <sup>4</sup>Dept of Medical Psychology, Amsterdam Medical Center, University Medical Center, Amsterdam, <sup>5</sup>Dept of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, <sup>6</sup>Dept of Gastroenterology and Hepatology, Amsterdam Medical Center, University Medical Center Amsterdam, <sup>7</sup>Family Cancer Clinic, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands*

- 14.00      Structural variant breakpoint detection in advanced colorectal cancer (p. 69 )  
*E. van den Broek<sup>1</sup>, O. Krijgsman<sup>1</sup>, D. Sie<sup>1</sup>, J.C. Haan<sup>1</sup>, M. Komor<sup>1</sup>, J. Traets<sup>1</sup>, D.A.M. Heideman<sup>1</sup>, M.A. van de Wiel<sup>2</sup>, I.D. Nagtegaal<sup>3</sup>, C.J.A. Punt<sup>4</sup>, B. Carvalho<sup>1</sup>, B. Ylstra<sup>1</sup>, G.A. Meijer<sup>1</sup>, R.J.A. Fijneman<sup>1</sup>, <sup>1</sup>Dept of Pathology, and <sup>2</sup>Dept of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, <sup>3</sup>Dept of Pathology, Radboud University, Nijmegen Medical Center, Nijmegen, <sup>4</sup>Dept of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands*
- 14.10      Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis (p. 70)  
*D.A.M. Sloothaak<sup>1</sup>, T.J. Gardenbroek<sup>1</sup>, J.Crezee<sup>3</sup>, W.A. Bemelman<sup>1</sup>, C.J.A Punt<sup>2</sup>, C.J. Buskens<sup>1</sup>, P.J. Tanis<sup>1</sup>, <sup>1</sup>Dept of Surgery, <sup>2</sup>Dept of Medical Oncology, and <sup>3</sup>Dept of Radiation Oncology, Academic Medical Center, Amsterdam, The Netherlands*
- 14.20      Urological procedures in patients with peritoneal carcinomatosis of colorectal cancer treated with HIPEC: Morbidity and survival analysis (p. 71)  
*H.J. Braam<sup>1</sup>, T.R. van Oudheusden<sup>2</sup>, I.H. de Hingh<sup>2</sup>, S.W. Nienhuijs<sup>2</sup>, D. Boerma<sup>1</sup>, M.J. Wiezer<sup>1</sup>, B. van Ramshorst<sup>1</sup>, <sup>1</sup>Dept of Surgery, St. Antonius Hospital, Nieuwegein, <sup>2</sup>Dept of Surgery, Catharina Hospital, Eindhoven, The Netherlands*
- 14.30      Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis (p. 72)  
*T.R. van Oudheusden<sup>1</sup>, H.J. Braam<sup>2</sup>, S.W. Nienhuijs<sup>1</sup>, M.J. Wiezer<sup>2</sup>, B. van Ramshorst<sup>2</sup>, M.D.P. Luyer<sup>1</sup>, I.H.J.T. de Hingh<sup>1</sup>, <sup>1</sup>Dept of Oncologic Surgery, Catharina Hospital, Eindhoven, <sup>2</sup>Dept of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands*
- 14.40      Oncological follow up of the Stent-In 2 trial: cancer recurrence after curative treatment of malignant colonic obstruction (p. 73)  
*D.A. Sloothaak<sup>1</sup>, M.W. van den Berg<sup>2</sup>, M.G. Dijkgraaf<sup>3,4</sup>, P. Fockens<sup>2,4</sup>, P.J. Tanis<sup>1,4</sup>, J.E. van Hooff<sup>2,4</sup>, W.A. Bemelman<sup>1,4</sup>, <sup>1</sup>Dept of Surgery, <sup>2</sup>Dept of Gastroenterology and Hepatology, and <sup>3</sup>Clinical Research Unit, Academic Medical Center, Amsterdam, <sup>4</sup>Stent-In study group, collaborative Dutch Stent-In study group, Amsterdam, The Netherlands*
- 14.50      Metachronous colorectal cancers: the clinician at fault? (p. 74)  
*C.M.C. le Clercq<sup>1</sup>, C.M. Bakker<sup>2</sup>, A. van Nunen<sup>2</sup>, E.T.P. Keulen<sup>3</sup>, G.L. Beets<sup>4</sup>, B. Winkens<sup>5</sup>, A.A.M. Masclee<sup>1</sup>, S. Sanduleanu<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Internal Medicine, Maastricht University Medical Center, Maastricht, <sup>2</sup>Dept of Gastroenterology, Atrium Medical Center, Heerlen, <sup>3</sup>Dept of Internal Medicine and Gastroenterology, Orbis Medical Center, Sittard, <sup>4</sup>Dept of Surgery, and <sup>5</sup>Dept of Methodology and Statistics, Maastricht University Medical Center, Maastricht, The Netherlands*
- 15.00      Theepauze in de expositiehal

Donderdag 20 maart 2014

---

**Voordrachten Nederlandse Vereniging voor Gastroenterologie**

**Brabantzaal**

---

**Voorzitters:** M. van Haastert en L.M.G. Moons

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

15.30 Inleiding op het programma door L.M.G. Moons

15.40 Computer assisted instruction before colonoscopy is as effective as nurse counselling, a controlled trial (p. 75)

*G. Veldhuijzen<sup>1</sup>, M. Klemt-Kropp<sup>1</sup>, C.G. Noomen<sup>1</sup>, T. van der Ploeg<sup>2</sup>, J.P.H. Drenth<sup>3</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Medical Centre Alkmaar, Alkmaar, The Netherlands, <sup>2</sup>Foreest Medical School, Medical Centre Alkmaar, Alkmaar, The Netherlands, <sup>3</sup>Dept of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands*

15.50 Implementing chromoendoscopy for surveillance in inflammatory bowel disease does not increase dysplasia detection compared to conventional colonoscopy with random biopsies: a retrospective study (p. 76)

*E. Mooiweer<sup>1</sup>, A.E. van der Meulen-de Jong<sup>2</sup>, E. Dekker<sup>3</sup>, C.Y. Ponsioen<sup>3</sup>, H.H. Fidder<sup>1</sup>, P.D. Siersema<sup>1</sup>, B. Oldenburg<sup>1</sup>, <sup>1</sup> University Medical Center Utrecht, Dept of Gastroenterology and Hepatology<sup>2</sup> Leiden University Medical Center, Dept of Gastroenterology and Hepatology<sup>3</sup> Amsterdam Medical Center, Dept of Gastroenterology and Hepatology*

16.00 Low inter-observer agreement among endoscopist in differentiating dysplastic from non-dysplastic lesions encountered during colitis surveillance (p. 77)

*L.K. Wanders<sup>1</sup>, E. Mooiweer<sup>2</sup>, P.D. Siersema<sup>2</sup>, R. Bisschops<sup>3</sup>, G.R.A.M. d'Haens<sup>1</sup>, B. Oldenburg<sup>2</sup>, E. Dekker<sup>1</sup>, <sup>1</sup> Dept of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, Netherlands <sup>2</sup>Dept of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, Netherlands <sup>3</sup>Dept of Medicine, Division of Gastroenterology, University Hospital Leuven, Leuven, Belgium*

16.10 Decreased colorectal cancer risk in Dutch ulcerative colitis patients: results from a population based cohort (p. 78)

*T.R.A. van den Heuvel<sup>1,2</sup>, M.H.H. Wassink<sup>1</sup>, S.F.G. Jeurings<sup>1,2</sup>, C.M.D. Glorie<sup>1</sup>, L.E. Oostenbrug<sup>3</sup>, M.J.L. Romberg-Camps<sup>4</sup>, W.H. Hammeeterman<sup>1</sup>, A.A.M. Masclee<sup>1,2</sup>, D.M.A.E. Jonkers<sup>1,2</sup>, M.J. Pierik<sup>1,2</sup>, <sup>1</sup>Maastricht University Medical Center+, Dept of Internal Medicine, Division of Gastroenterology-Hepatology, Maastricht, The Netherlands. <sup>2</sup>Maastricht University Medical Center+, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht, The Netherlands. <sup>3</sup>Atrium Medical Center, Dept of Internal Medicine, Heerlen, The Netherlands. <sup>4</sup>Orbis Medical Center, Dept of Internal Medicine, Sittard-Geleen, The Netherlands.*

16.20 Incidence of interval colorectal cancer among inflammatory bowel disease patients enrolled in a colonoscopic surveillance program (p. 79)

*W. Kremer<sup>1</sup>, E. Mooiweer<sup>1</sup>, A.E. van der Meulen – de Jong<sup>2</sup>, C.Y. Ponsioen<sup>3</sup>, C.J. van der Woude<sup>4</sup>, A.A. van Bodegraven<sup>5</sup>, J.M. Jansen<sup>6</sup>, N. Mahmood<sup>7</sup>, P.D. Siersema<sup>1</sup>, B. Oldenburg<sup>1</sup>, <sup>1</sup> University Medical Center Utrecht, Dept of Gastroenterology and Hepatology <sup>2</sup>Leiden University Medical Center, Dept of Gastroenterology and Hepatology <sup>3</sup>Amsterdam Medical Center, Dept of Gastroenterology and*

Donderdag 20 maart 2014

Hepatology <sup>4</sup>Erasmus Medical Center Rotterdam, Dept of Gastroenterology and Hepatology <sup>5</sup>VU Medical Center Amsterdam, Dept of Gastroenterology and Hepatology <sup>6</sup>OLVG Amsterdam, Dept of Gastroenterology and Hepatology <sup>7</sup>St Antonius Hospital Nieuwegein, Dept of Gastroenterology and Hepatology

16.30 Faecal calprotectine does not differentiate between IBD and a juvenile polyp (p. 80)

V.G. Pluimakers<sup>1</sup>, F.T.M. Kokke<sup>1</sup>, P.G.J. Nikkels<sup>2</sup>, M.L. Houben<sup>3</sup>, R.H.J. Houwen<sup>1</sup>, V.M. Wolters<sup>1</sup>, <sup>1</sup>WKZ/UMC Utrecht, Dept of pediatric gastroenterology <sup>2</sup>UMC Utrecht, Dept of Pathology <sup>3</sup>WKZ/UMC Utrecht, Dept of General Pediatrics

16.40 Fecal immunochemical testing results vary depending on characteristics of colonic lesions (p. 81)

S.C. van Doorn<sup>1</sup>; I. Stegeman<sup>2</sup>; A.K. Stroobants<sup>3</sup>, M.W. Mundt<sup>4</sup>, T.R. de Wijkerslooth<sup>1</sup>; P. Fockens<sup>1</sup>; E.J. Kuipers<sup>5</sup>, P.M. Bossuyt<sup>2</sup>; E. Dekker<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, Netherlands. <sup>2</sup>Dept of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, Netherlands. <sup>3</sup>Dept of Clinical Chemistry. <sup>4</sup>Dept of Gastroenterology and Hepatology, Flevoziekenhuis Almere. <sup>5</sup>Erasmus Medical Center, Rotterdam, the Netherlands

16.50 Synchronous/metachronous neoplasms predict the presence of lateral spreading tumors (p. 82)

R.M.M. Bogie<sup>1</sup>, C.M.C. le Clercq<sup>1</sup>, M.W.E. Bouwens<sup>1</sup>, B. Winkens<sup>2</sup>, R. de Ridder<sup>1</sup>, T. Kaltenbach<sup>3</sup>, R. Soetikno<sup>3</sup>, A.A.M. Masclee<sup>1</sup>, S. Sanduleanu<sup>1</sup>, <sup>1</sup>Division of Gastroenterology and Hepatology; Maastricht University Medical Center, The Netherlands, <sup>2</sup>Dept of Methodology and Statistics, Maastricht University Medical Center, the Netherlands, <sup>3</sup>VA Healthcare System, Palo Alto, Stanford School of Medicine, USA

Donderdag 20 maart 2014

---

**Prijsuitreiking**

**Brabantzaal**

---

**Voorzitter:** P.D. Siersema

- 17.00      **Uitreiking van de Frieda den Hartog Jager Prijs**  
gevolgd door erevoordracht: "Pathogenese en preventie van colorectaal  
carcinoom: the continuing story"  
*Prof. dr. J.H. Kleibeuker, MDL-arts, Universitair Medisch Centrum  
Groningen*

---

**Voordrachten President Select**

**Brabantzaal**

---

**Voorzitter:** P.D. Siersema

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

- 17.30      Experience in over 150 patients with the EndoBarrier® / duodenal jejunal  
bypass liner (p. 83)  
*B. Betzel<sup>1</sup>, P. Koehestanie<sup>1</sup>, K. Dogan<sup>1</sup>, J. Homan<sup>1</sup>, E.O. Aarts<sup>1</sup>, I.M.C. Janssen<sup>1</sup>, F.J. Berends<sup>1</sup>, P.J.  
Wahab<sup>2</sup>, M.J.M. Groenen<sup>2</sup>, Dept of Surgery<sup>1</sup> and Gastroenterology<sup>2</sup>, Rijnstate Hospital the Netherlands*
- 17.40      Long-term outcome of low perianal fistulas treated by fistulotomy (p. 84)  
*P.T.J. Janssen<sup>1</sup>, K. Göttgens<sup>1</sup>, J. Heemskerk<sup>2</sup>, F. van Dielen<sup>3</sup>, J. Konsten<sup>4</sup>, T. Lettinga<sup>5</sup>, T. Hoofwijk<sup>6</sup>, .L.  
Beets<sup>1</sup>, L.P.S. Stassen<sup>1</sup>, S.O. Breukink<sup>1</sup>, <sup>1</sup>Dept of Surgery, Maastricht University Medical Center,  
Maastricht, The Netherlands, <sup>2</sup>Dept of Surgery, Laurentius Hospital, Roermond, The Netherlands, <sup>3</sup>Dept  
of Surgery, Maxima, Medical Center, Veldhoven, The Netherlands, <sup>4</sup>Dept of Surgery, VieCuri, Medical  
Center, Venlo, The Netherlands, <sup>5</sup>Dept of Surgery, St. Jans Gasthuis, Weert, The Netherlands, <sup>6</sup>Dept of  
Surgery, Orbis Medical Center, Sittard, The Netherlands*
- 17.50      Genome-wide association study in autoimmune hepatitis identifies risk  
variant in the SH2B3 region (p. 85)  
*Y.S. de Boer<sup>1,§</sup>, N.M.F. van Gerven<sup>1,§</sup>, A. Zwieters<sup>1,2</sup>, B. Verwer<sup>1</sup>, B. van Hoek<sup>3</sup>, K. J. van Erpecum<sup>4</sup>,  
U.H.W. Beuers<sup>5</sup>, H.R. van Buuren<sup>6</sup>, J.P.H. Drenth<sup>7</sup>, J.W. den Ouden<sup>8</sup>, R.C. Verdonk<sup>9,10</sup>, G.H. Koek<sup>11</sup>,  
J.T. Brouwer<sup>12</sup>, M.M.J. Guichelaar<sup>13</sup>, J.M. Vrolijk<sup>14</sup>, G. Kraal<sup>2</sup>, C. J.J. Mulder<sup>1</sup>, C.M.J. van Nieuwkerk<sup>1</sup>,  
J. Fischer<sup>15</sup>, T. Berg<sup>15</sup>, F. Stickel<sup>16</sup>, C. Sarrazin<sup>17</sup>, C. Schramm<sup>18</sup>, A.W. Lohse<sup>18</sup>, C. Weiler-Normann<sup>18</sup>,  
M.M. Lerch<sup>19</sup>, M. Nauck<sup>20</sup>, H. Völzke<sup>21</sup>, G. Homuth<sup>22</sup>, E. Bloemena<sup>23</sup>, V. Kumar<sup>24</sup>, A. Zhernakova<sup>24</sup>, C.  
Wijmenga<sup>24</sup>, L. Franke<sup>24,\$</sup>, G. Bouma<sup>1,2,\$</sup>; The Dutch Autoimmune Hepatitis Study Group, The LifeLines  
Cohort study, The Study of Health in Pomerania (SHIP) # These authors contributed equally to this  
manuscript, \$ These authors contributed equally to this manuscript, <sup>1</sup>Dept of Gastroenterology and  
Hepatology, VU University Medical Center, Amsterdam, The Netherlands <sup>2</sup>Dept of Molecular Cell Biology  
and Immunology, VU University Medical Center, Amsterdam, The Netherlands <sup>3</sup>Dept of Gastroenterology  
and Hepatology, Leiden University Medical Center, Leiden, The Netherlands <sup>4</sup>Dept of Gastroenterology  
and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands <sup>5</sup>Dept of Gastroenterology  
and Hepatology, Academic Medical Center, Amsterdam, The Netherlands <sup>6</sup>Dept of Gastroenterology and  
Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands <sup>7</sup>Dept of Gastroenterology  
and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands <sup>8</sup>Dept of  
Gastroenterology and Hepatology, Haga Hospital, The Hague, The Netherlands <sup>9</sup>University of Groningen*

Donderdag 20 maart 2014

University Medical Center Groningen, Dept of Gastroenterology and Hepatology, Groningen, The Netherlands <sup>10</sup>Dept of Gastroenterology and Hepatology, St Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands <sup>11</sup>Dept of Gastroenterology and Hepatology, University Medical Center Maastricht, Maastricht, The Netherlands <sup>12</sup>Dept of Gastroenterology and Hepatology, Reinier de Graaf Hospital, Delft, The Netherlands <sup>13</sup>Dept of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, The Netherlands <sup>14</sup>Dept of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, The Netherlands <sup>15</sup>Dept of Internal Medicine, Neurology and Dermatology, Medical Clinic of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany <sup>16</sup>Dept of Visceral Surgery and Medicine, Inselspital, University of Bern, Bern, Switzerland <sup>17</sup>Dept of Medicine I, University of Frankfurt/M., Frankfurt, Germany <sup>18</sup>Dept of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany <sup>19</sup>Dept of Internal Medicine A, University Medicine Greifswald, Greifswald, Germany <sup>20</sup>Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany <sup>21</sup>Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany <sup>22</sup>Interfaculty Institute for Genetics and Functional Genomics, University Medicine and Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany <sup>23</sup>Dept of Pathology, VU University Medical Center, Amsterdam, The Netherlands <sup>24</sup>University of Groningen, University Medical Center Groningen, Dept of Genetics, Groningen, The Netherlands

---

**State of the art lecture****Brabantzaal**

---

**Voorzitter:** P.D. Siersema

- 18.00      **Challenges of Translational GI Research**  
*Prof. dr. E.M. El-Omar, professor of Gastroenterology*  
*Institute of Medical Sciences, Aberdeen University, U.K.*
- 18.30      Einde programma, congresborrel in expositiehal.

Donderdag 20 maart 2014

---

**Nederlandse Vereniging voor Gastrointestinale Chirurgie**

**Auditorium**

---

**Voorzitter:** F. Daams en J. Heisterkamp

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

- 09.30      In vivo spectroscopy on tissues encountered during colorectal surgery (p. 86)  
*R.M. Schols<sup>1,2</sup>, L. Alic<sup>2</sup>, G.L. Beets<sup>1</sup>, S.O. Breukink<sup>1</sup>, F.P. Wieringa<sup>2</sup>, L.P.S. Stassen<sup>1</sup>, <sup>1</sup>Dept of Surgery, Maastricht University Medical Center & NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University, Maastricht, <sup>2</sup>van 't Hoff Program on Medical Photonics, Netherlands Organization for Applied Scientific Research TNO, Eindhoven, The Netherlands*
- 09.40      The use of endoractor during laparoscopic colorectal surgery; a new solution? pilot study (p. 87)  
*J.S. Pawiroredjo<sup>1</sup>, N. Rijkers<sup>1</sup>, A.B. Smits<sup>1</sup>, <sup>1</sup>Sint Antonius Ziekenhuis, Nieuwegein, The Netherlands*
- 09.50      Analysis of open-close HIPEC-procedure patients in peritoneal metastasis of colorectal origin (p. 88)  
*T.R. van Oudheusden<sup>1</sup>, H.J. Braam<sup>2</sup>, S.W. Nienhuijs<sup>1</sup>, M.J. Wiezer<sup>2</sup>, B. van Ramshorst<sup>2</sup>, M.D.P. Luyer<sup>1</sup>, I.H.J.T. de Hingh<sup>1</sup>, <sup>1</sup>Dept of Surgery, Catharina Hospital, Eindhoven, <sup>2</sup>Dept of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands*
- 10.00      Transanal versus traditional laparoscopic total mesorectal excision for rectal carcinomaA matched case control study (p. 89)  
*S. Velthuis<sup>1</sup>, D.H. Nieuwenhuis<sup>1</sup>, T.E.G. Ruijter<sup>2</sup>, M.A. Cuesta<sup>1</sup>, H.J. Bonjer<sup>1</sup>, C. Sietses<sup>1</sup>, <sup>1</sup>Dept of Surgery, Gelderse Vallei Hospital, Ede, <sup>2</sup>Dept of Surgery, VU Medical Center, Amsterdam, <sup>3</sup>Dept of Pathology, Rijnstate Hospital, Arnhem, The Netherlands*
- 10.10      Management of major perineal wound complications after abdominoperineal resection for malignant disease. A retrospective cohort study (p. 90)  
*M.S. Walma<sup>1</sup>, J.P.M. Burbach<sup>1</sup>, P.M. Verheijen<sup>2</sup>, R. van Hillegersberg<sup>1</sup>, A. Pronk<sup>3</sup>, W.M.U. van Grevenstein<sup>1</sup>, <sup>1</sup>Universitary Medical Center Utrecht, Utrecht, <sup>2</sup>Meander Medical Center, Amersfoort, <sup>3</sup>Diakonessenhuis, Utrecht, The Netherlands*
- 10.20      The detrimental effect of diclofenac on intestinal anastomotic healing depends on the location in the gut (p. 91)  
*S.T.K. Yauw<sup>1</sup>, R.M.L.M. Lomme<sup>1</sup>, R.J. van der Vijver<sup>1</sup>, T. Hendriks<sup>1</sup>, H. van Goor<sup>1</sup>, <sup>1</sup>Dept of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands*
- 10.30      Defunctioning ileostomy does not prevent anastomotic leaks after restorative proctocolectomy; a multicenter evaluation of clinical and surgical risk factors (p. 92)  
*S. Sahami<sup>1</sup>, C.J. Buskens<sup>1</sup>, R. Lindeboom<sup>2</sup>, T. Young Fadok<sup>3</sup>, A. de Buck van Overstraeten<sup>4</sup>, A. D'Hoore<sup>4</sup>, W.A. Bemelman<sup>1</sup>, <sup>1</sup>Dept of Surgery, Academic Medical Center, Amsterdam, <sup>2</sup>Divisions of Clinical Methods and Public Health, Academic Medical Center, Amsterdam, The Netherlands, <sup>3</sup>Dept of Surgery, Mayo Clinic College of Medicine, Arizona, USA, <sup>4</sup>Dept of Surgery, University Hospitals Leuven,*

Donderdag 20 maart 2014

- 10.40      **The course of pulmonary vagus nerve branches (p. 93)**  
*T.J. Weijs<sup>1</sup>, J.P. Ruurda<sup>2</sup>, M.D.P. Luyer<sup>3</sup>, G.A.P. Nieuwenhuijzen<sup>3</sup>, R. van Hillegersberg<sup>2</sup>, R.L.A.W. Bleys<sup>1</sup>, <sup>1</sup>Dept of Anatomy, and <sup>2</sup>Dept of Surgical Oncology, University Medical Center Utrecht, Utrecht, <sup>3</sup>Dept of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands*
- 10.50      **Near-infrared fluorescence sentinel lymph node detection in gastric cancer using indocyanine green coupled to a nanocolloid (p. 94)**  
*Q.R.J.G. Tummers<sup>1</sup>, L.S.F. Boogerd<sup>1</sup>, F.P.R. Verbeek<sup>1</sup>, M.C. Boonstra<sup>1</sup>, H.J.M. Handgraaf<sup>1</sup>, H.H. Hartgrink<sup>1</sup>, W.O. de Steur<sup>1</sup>, J.V. Frangioni<sup>2,3</sup>, C.J.H. van de Velde<sup>1</sup>, A.L. Vahrmeijer<sup>1</sup>, <sup>1</sup>Dept of Surgery, Leiden University Medical Center, Leiden, The Netherlands, <sup>2</sup>Dept of Medicine, and <sup>3</sup>Dept of Radiology, Beth Israel Deaconess Medical Center, Boston, USA*
- 11.00      **Worldwide trends in surgical techniques in the treatment of esophageal cancer (p. 95)**  
*L. Haverkamp<sup>1</sup>, J.P. Ruurda<sup>1</sup>, J. Boone<sup>2</sup>, R. van Hillegersberg<sup>1</sup>, <sup>1</sup>University Medical Center Utrecht, Utrecht, The Netherlands*
- 11.10      **Thoracolaparoscopic dissection of lymph nodes involved in the drainage of the esophagus is feasible and safe in human cadavers and swine (p. 96)**  
*H.T. Künzli<sup>1,4</sup>, M.I. van Berge Henegouwen<sup>5</sup>, S.S. Gisbertz<sup>5</sup>, M.J. Wiezer<sup>2</sup>, C.A. Seldenrijk<sup>3</sup>, J.J.G.H.M. Bergman<sup>4</sup>, B.L.A.M. Weusten<sup>1,4</sup>, <sup>1</sup>Dept of Gastroenterology, <sup>2</sup>Dept of Surgery, and <sup>3</sup>Dept of Pathology, St. Antonius Hospital, Nieuwegein, <sup>4</sup>Dept of Gastroenterology, and <sup>5</sup>Dept of Surgery, Academic Medical Center, Amsterdam, The Netherlands*
- 11.20      **Effect of perioperatively administered glucocorticoids on pulmonary complications after transthoracic oesophagectomy. A meta-analysis (p. 97)**  
*T.J. Weijs<sup>1</sup>, J.M. Dieleman<sup>2</sup>, J.P. Ruurda<sup>1</sup>, A.C. Kroese<sup>2</sup>, H.J.T.A. Knape<sup>2</sup>, R. van Hillegersberg<sup>1</sup>, <sup>1</sup>Dept of Surgical Oncology, Surgery, <sup>2</sup>Dept of Anaesthesiology, Intensive Care and Emergency Medicine, University Medical Center Utrecht, Utrecht, The Netherlands*
- 11.30      **Ledenvergadering Nederlandse Vereniging voor Gastroenterologie in de Brabantzaal**
- 12.00      **Lunchbuffet in de expositiehal**

Donderdag 20 maart 2014

---

**Symposium Ned. Vereniging voor Gastrointestinale Chirurgie**

**Auditorium**

---

**Voorzitters:** E. Dekker en C. Hoff

**Van anussparende chirurgie tot rectumsparende endoscopie**

In tegenstelling tot de aankondiging in het eerder toegezonden programma zullen de uitkomsten van de TREND studie niet gepresenteerd worden.

- 13.00 TAMIS  
*Dr. C. Sietses, chirurg, Ziekenhuis Gelderse Vallei, Ede*
- 13.20 TEM voor en na chemoradiatie  
*Prof. dr. J.H.W. de Wilt, chirurg, Radboudumc, Nijmegen*
- 13.40 Maatwerk in de preoperatieve radiatie bij het rectumcarcinoom  
*Radiotherapeut, namens de richtlijnwerkgroep*
- 14.00 TEM vs endoscopische poliepectomie: een literatuur overzicht  
*J.W.A. Leijtens, chirurg, Laurentius Ziekenhuis, Roermond*
- 14.20 Discussie
- 14.30 Innovations in colorectal surgery round 1 (room 82 + 83)
- 15.00 Theepauze expositiehal

---

**Symposium Ned. Vereniging voor Gastrointestinale Chirurgie**

**Auditorium**

---

**Voorzitters:** P.P.L.O. Coene en M. Ledeboer

**Uitkomsten en transparantie van de colorectale diagnostiek en chirurgie**

- 15.30 Landelijke registratie endoscopie en complicatieregistratie.  
*Dr. M. Ledeboer, MDL-arts, Deventer Ziekenhuis*

Donderdag 20 maart 2014

- 15.50 DSCA: validatie van de data  
*Dr. M. Wouters, chirurg, Antoni van Leeuwenhoekhuis en secretaris  
kwaliteit bestuur NVVH*
- 16.10 Is de case mix correctie adequaat voor complexe combinaties van  
patiënten en procedures?  
*Dr. P. Tanis, chirurg, Academisch Medisch Centrum, Amsterdam*
- 16.30 Winst van deviatie na rectumchirurgie: winst voor de patiënt of voor de  
'score'?  
*Dr. J.W. Dekker, chirurg, Reinier de Graaf Gasthuis, Delft*
- 16.50 Gebruik bij prothetisch materiaal bij functionele rectumchirurgie: zit ook  
hier de toekomst in auditing?  
*Dr. N.A.T. Wijffels, chirurg, Zuwe Hofpoort, Woerden*
- 17.10 Innovations in colorectal surgery round 2 (room 82 + 83)
- 17.30 Voor de President Select kunt u zich begeven naar de Brabantzaal
- 18.30 Einde programma, congresborrel in expositiehal.

Donderdag 20 maart 2014

---

**DEGH-Meeting**

**Baroniezaal**

---

**Voorzitters:** J.P.H. Drenth en C.C. Paulusma

Voordrachten in het Engels, spreektijd 8 minuten, discussietijd 4 minuten

- 10.30 Introduction to the abstracts  
*Prof. dr. J.P.H. Drenth, MDL-arts, Radboudumc Nijmegen*
- 11.00 Fucosyltransferase-2 non-secretor status is associated with non-anastomotic biliary strictures after liver transplantation in recipients with primary sclerosing cholangitis (p. 98)  
*C.J. Verhoeven<sup>1</sup>, L. Maroni<sup>2</sup>, P. Gadjradj<sup>1</sup>, D. Tolenaars<sup>2</sup>, E. de Mare-Bredemeijer<sup>3</sup>, S. Mancham<sup>3</sup>, S. van de Graaf<sup>2</sup>, R. Oude Elferink<sup>2</sup>, U. Beuers<sup>2</sup>, H.J. Metselaar<sup>3</sup>, J. Kwekkeboom<sup>3</sup>, L.J.W. van der Laan<sup>1</sup>, <sup>1</sup>Dept of Surgery, and <sup>3</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>2</sup>Dept of Gastroenterology and Hepatology, Tytgat Institute, Academic Medical Center, Amsterdam, The Netherlands*
- 11.12 Local administration of bone marrow-derived mesenchymal stromal cells after partial hepatectomy ameliorates liver fibrogenesis in a dose dependent manner (p. 99)  
*D. van der Helm<sup>1</sup>, E.S.M. de Jonge-Muller<sup>1</sup>, B. van Hoek<sup>1</sup>, I. Molendijk<sup>1</sup>, A.C. den Dulk<sup>1</sup>, J.J. van der Reijden<sup>1</sup>, I. Biemond<sup>1</sup>, M.J. Coenraad<sup>1</sup>, H.W. Verspaget<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands*
- 11.24 Dopamine protects against cooling and rewarming-induced liver damage in vitro and in vivo (p. 100)  
*E.M. Verhaag<sup>1,2</sup>, H. Room<sup>1</sup>, N. Verhoeff<sup>1</sup>, G.J. Dugbartey<sup>2</sup>, H. Moshage<sup>1</sup>, R.H. Henning<sup>2</sup>, K.N. Faber<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, <sup>2</sup>Dept of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands*
- 11.36 Decellularization of human and porcine livers: Applications for graft engineering (p. 101)  
*M.M.A. Verstegen<sup>1</sup>, S. van den Hoek<sup>1</sup>, J. Kwekkeboom<sup>2</sup>, H.J. Metselaar<sup>2</sup>, J. IJzermans<sup>1</sup>, L.J.W. van der Laan<sup>1</sup>, J. de Jonge<sup>1</sup>, <sup>1</sup>Dept of Surgery, and <sup>2</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands*
- 11.48 Smad4-dependent regulation of hepatocellular carcinoma growth and progression (p. 102)  
*P.Y. Hernanda<sup>1</sup>, C. Kan<sup>1</sup>, A.M. Das<sup>2</sup>, K. Sideras<sup>1</sup>, S.J.A Bots<sup>1</sup>, H.L.A. Janssen<sup>1,3</sup>, L.L. Kodach<sup>4</sup>, H.J. Metselaar<sup>1</sup>, J.Kwekkeboom<sup>1</sup>, D. Sprengers<sup>1</sup>, M.J. Bruno<sup>1</sup>, T.L.M. ten Hagen<sup>2</sup>, M.P. Peppelenbosch<sup>1</sup>, Q.Pan<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, and <sup>2</sup>Laboratory of Experimental Surgical Oncology, Section Surgical Oncology, Dept of Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, <sup>3</sup>Division of Gastroenterology, University Health Network, Toronto, Canada, <sup>4</sup>Dept of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands*
- 12.00 Lunchbuffet in de expositiehal

---

**DEGH oral presentations**

**Baroniezaal**

---

**Voorzitters:** G.A. Meijer en S.W.C. van Mil

Voordrachten in het Engels, spreektijd 8 minuten, discussietijd 4 minuten

- 13.00      Translational Science Teaching session : Colorectal Carcinoma (CRC)  
*Prof. dr. G.A. Meijer, VU medisch centrum, Amsterdam*
- 13.30      Sensitization of colon cancer stem cells to chemotherapy by ER stress induced differentiation (p. 103)  
*M.C.B. Wielenga<sup>1\*</sup>, S. Colak<sup>2\*</sup>, J. Heijmans<sup>1</sup>, J.F. van Lidth de Jeude<sup>1</sup>, S.L. Rosekrans<sup>1</sup>, B. Baan<sup>1</sup>, J.P. Medema<sup>2</sup>, G.R. van den Brink<sup>1</sup>, \*Both authors contributed equally, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, and <sup>2</sup>Laboratory of Experimental Oncology and Radiobiology, Academic Medical Center, Amsterdam, The Netherlands*
- 13.42      Inhibited expression of corticotropin-releasing hormone receptor 2 (CRHR2) correlates with tumor growth, EMT, distant metastasis risk and poor survival in experimental and clinical colorectal cancer (p. 104)  
*J. Rodriguez<sup>1</sup>, H.W. Verspaget<sup>2</sup>, D. Iliopoulos<sup>1</sup>, S.H. Ypez<sup>3</sup>, J.M. Hoffman<sup>1</sup>, G.J. Baay-Gusman<sup>3</sup>, A.B. Tirado-Rodriguez<sup>3</sup>, I.K.M. Law<sup>1</sup>, D.W. Hommes<sup>1,2</sup>, L. Chang<sup>1</sup>, Ch. Pothoulakis<sup>1</sup>, S. Baritaki<sup>1</sup>, <sup>1</sup>Division of Digestive Diseases and Institute for Molecular Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA, <sup>2</sup>Dept of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands, <sup>3</sup>Unidad de Investigacion en Enfermedades Oncologicas, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico*
- 13.54      Dual targeting of the VEGF and endoglin/TGF- $\beta$  pathway in colorectal cancer (p. 105)  
*M. Paauwe<sup>1</sup>, R.C. Heijkants<sup>1</sup>, G.W. van Pelt<sup>2</sup>, W.E. Mesker<sup>2</sup>, C.F.M. Sier<sup>2</sup>, C.P. Theuer<sup>3</sup>, L.J.A.C. Hawinkels<sup>1</sup>, <sup>1</sup>Dept of Molecular Cell Biology, and <sup>2</sup>Dept of Surgery, Leiden University Medical Center, Leiden, The Netherlands, <sup>3</sup>Tracon Pharmaceuticals, San Diego, USA*
- 14.06      Conditional activation of BMP signalling leads to loss of the stem cell compartment (p. 106)  
*P. Voorneveld<sup>1</sup>, L. Kodach<sup>1</sup>, R. Jacobs<sup>1</sup>, S. Rozekrans<sup>2,3</sup>, G. van den Brink<sup>2,3</sup>, J. Hardwick<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>2</sup>Dept of Gastroenterology and Hepatology, and <sup>3</sup>Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, The Netherlands*
- 14.18      Protein tyrosine phosphatase 1B (PTP1B) expression and phosphatase activity are increased in colorectal cancer which leads to a more invasive phenotype (p. 107)  
*E. Hoekstra<sup>1</sup>, M.J. Bruno<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, G.M. Fuhler<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands*

Donderdag 20 maart 2014

14.30 ER stress depletes Apc mutant intestinal epithelial stem cells downstream of nuclear  $\beta$ -catenin (p. 108)

*J.F. van Lidth de Jeude<sup>1</sup>, M.C.B. Wielenga<sup>1</sup>, S.L. Rosekrans<sup>1</sup>, V. Muncan<sup>1</sup>, G.R. van den Brink<sup>1</sup>, J. Heijmans<sup>1</sup>, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands*

14.42 Fibroblasts promote invasion in SMAD4 negative colorectal cancers by producing BMP-2 (p. 109)

*P.W. Voorneveld<sup>1</sup>, T. de Vos<sup>1</sup>, S. de Wit<sup>1</sup>, R.J. Jacobs<sup>1</sup>, L. Hawinkels<sup>2</sup>, M. Paauwe<sup>2</sup>, G. van Pelt<sup>3</sup>, W. Mesker<sup>3</sup>, G.R. van den Brink<sup>4,5</sup>, L. Kodach<sup>1</sup>, J. Hardwick<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, <sup>2</sup>Dept of Molecular Cell Biology, Cancer Genomics Center Netherlands and Center for Biomedical Genetics, and <sup>3</sup>Dept of Surgery, Leiden University Medical Center, Leiden, <sup>4</sup>Tytgat Institute for Liver and Intestinal Research, and <sup>5</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands*

15.00 Ledenvergadering Nederlandse Vereniging voor Hepatologie

**Voorzitters:** P.A. Boonstra en R.J. de Knegt

Voordrachten in het Engels, spreektijd 8 minuten, discussietijd 4 minuten

15.30 Translational science Teaching Session: Viral Hepatitis  
Clinical aspects: *Dr. R.J. De Knegt, Erasmus MC, Rotterdam*

15.57 Basic/Translational science aspects: *Dr. P.A. Boonstra, Erasmus MC, Rotterdam*

16.24 Baseline liver gene expression profile associated with combined response in chronic hepatitis B patients treated with peginterferon and adefovir (p. 110)

*F. Stelma<sup>1,2</sup>, L. Jansen<sup>1,2</sup>, A. de Niet<sup>1,2</sup>, Z. Makowska<sup>3</sup>, M. T. Dill<sup>3</sup>, K. A. van Dort<sup>2</sup>, R. B. Takkenberg<sup>1</sup>, M.H. Heim<sup>3</sup>, N. A. Kootstra<sup>2</sup>, H.W. Reesink<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, and <sup>2</sup>Dept of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, <sup>3</sup>Dept of Biomedicine, University of Basel, Basel, Switzerland*

16.36 Dichotomal effect of immunosuppressants on hepatitis e virus infection: calcineurin inhibitors stimulate but mycophenolic acid inhibits viral replication (p. 111)

*Y. Wang<sup>1</sup>, X. Zhou<sup>1</sup>, Y. Debing<sup>2</sup>, L.J.W. van der Laan<sup>3</sup>, J. Neyts<sup>2</sup>, H.L.A. Janssen<sup>1,4</sup>, H.J. Metselaar<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, Q. Pan<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, <sup>2</sup>Rega Institute for Medical Research, Dept of Microbiology and Immunology, KU Leuven, Leuven, Belgium, <sup>3</sup>Dept of Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, <sup>4</sup>Division of Gastroenterology, University Health Network, Toronto, Canada*

Donderdag 20 maart 2014

- 16.48      Active genuine HBV replication in human liver chimeric uPA<sup>+/+</sup> NOG mice (p. 112)  
*M.D.B. van de Garde<sup>1</sup>, P. Biesta<sup>1</sup>, K. de Groot-Kreeft<sup>1</sup>, H.L.A. Janssen<sup>1,2</sup>, A. Boonstra<sup>1</sup>, T. Vanwolleghem<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands, <sup>2</sup>Liver Clinic, Toronto Western and General Hospital University Health Network Toronto, Toronto, Canada*
- 17.00      Voor de uitreiking van de Frieda den Hartog Jager prijs met aansluitende lezing door Prof. dr. J.H. Kleibeuker kunt u zich begeven naar de Brabantzaal

**Voorzitters:** J.C. Escher en S.W.M. Olde Damink

**Symposium Darmfalen**

Van de secties: Kinder-MDL, NESPEN en NVGIC van de NVGE

- 9.30            Inleiding: Stichting Darmfalen Nederland en DRIFT  
*Prof. dr. G. Dijkstra, MDL-arts, UMC Groningen*
- 9.35            Eerste resultaten van Dutch Registry for Intestinal Failure  
*Prof. dr. E.H.H.M. Rings, kinderarts, Erasmus MC Rotterdam & Leids UMC*

**Behandeling van darmfalen**

- 9.50            Behandeling short bowel syndroom bij volwassenen  
*Dr. G. Wanten, MDL-arts, Radboudumc, Nijmegen*
- 10.05          Darmrevalidatie bij kinderen  
*Dr. J.M. Hulst, kinderarts, Erasmus MC, Rotterdam*
- 10.15          Parenterale voeding bij volwassenen  
*Dr. M.J. Serlie, internist-endocrinoloog, AMC, Amsterdam*

**Chirurgie bij darmfalen**

- 10.25          Kinderchirurgie bij darmfalen  
*Prof. dr. R.M.H. Wijnen, kinderchirurg, Erasmus MC, Rotterdam*
- 10.40          Reconstructie chirurgie bij darmfalen van volwassenen  
*Prof. dr. M.A. Boermeester, chirurg, Academisch Medisch Centrum Amsterdam*
- 10.55          Dunnedarmtransplantatie bij kinderen en volwassenen  
*Dr. J.W. Haveman, chirurg, UMC Groningen*
- 11.10          Plaatsbepaling en outcome van dunnedarmtransplantatie in Nederland  
*Prof. dr. G. Dijkstra, MDL-arts, UMC Groningen*

Donderdag 20 maart 2014

- 11.25 Einde symposium
- 11.30 Voor de ledenvergadering van de NVGE kunt u zich begeven naar de Brabantzaal
- 12.00 Lunchbuffet in de expositiehal

---

**Vrije voordrachten Sectie Inflammatoire Darmziekten**

**Parkzaal**

---

**Voorzitters:** G.R.A.M. D'Haens en W.R. ten Hove

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

- 13.00 Gene expression profiles in peripheral blood as early biomarkers for response to induction therapy in Crohn's disease (p. 113)  
*C.P. Peters<sup>1,2</sup>, F.H. van Dooren<sup>1</sup>, N.W. Duijvis<sup>1</sup>, P.C.F. Stokkers<sup>3</sup>, P.D. Moerland<sup>4</sup>, C.Y. Ponsioen<sup>2</sup>, A.A. te Velde<sup>1</sup>, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, and <sup>2</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, <sup>3</sup>Dept of Gastroenterology and Hepatology, St Lucas Andreas Hospital, Amsterdam, <sup>4</sup>Dept of Clinical Epidemiology, Biostatistics and Bioinformatics, Bioinformatics Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands*
- 13.10 NCF4 risk allele affects steroid exposure and dependency in Crohn's disease patients, preliminary results (p. 114)  
*V.J.A.A. Nuij<sup>1</sup>, R. Somasundaram<sup>1</sup>, K. Diederik<sup>1</sup>, L. Vellekoop<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, C. J. van der Woude<sup>1</sup>, G.M. Fuhler<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.*
- 13.20 Fibrosis does not increase with disease duration in ulcerative colitis (p. 115)  
*J.R. de Bruyn<sup>1,2</sup>, S.L. Meijer<sup>3</sup>, M.E. Wildenberg<sup>2</sup>, G.R. van den Brink<sup>1,2</sup>, G.R.A.M. D'Haens<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology, <sup>2</sup>Tytgat Institute for Liver and Intestinal Research, and <sup>3</sup>Dept of Pathology, Academic Medical Center, Amsterdam, The Netherlands*
- 13.30 Identification of HLA-A and WWOX as genetic variants associated with recurrent fibrostenotic Crohn's disease (p. 116)  
*M.C. Visschedijk<sup>1,2</sup>, L.M. Spekhorst<sup>1</sup>, E.S. van Loo<sup>3</sup>, D. de Jong<sup>4</sup>, A.E. van der Meulen-de Jong<sup>5</sup>, H.W. Verspaget<sup>5</sup>, C.Y. Ponsioen<sup>6</sup>, V.B. Nieuwenhuijs<sup>7</sup>, R. Alberts<sup>2</sup>, S. van Sommeren<sup>1,2</sup>, G. Dijkstra<sup>1</sup>, R.K. Weersma<sup>1</sup>, E.A.M. Festen<sup>1,2</sup>, On behalf of the Initiative on Crohn and Colitis, <sup>1</sup>Dept of Gastroenterology and Hepatology, <sup>2</sup>Dept of Genetics, and <sup>3</sup>Dept of Surgery, University of Groningen, University Medical Center Groningen, Groningen, <sup>4</sup>Dept of Gastroenterology and Hepatology, Radboud University, Nijmegen Medical Center, Nijmegen, <sup>5</sup>Dept of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>6</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, <sup>7</sup>Dept of Surgery, Isala Clinics, Zwolle, The Netherlands*

Donderdag 20 maart 2014

- 13.40      Leukocyte Scintigraphy as a Tool to Measure Inflammatory Load in Ulcerative Colitis (p. 117)  
*J.F. Brandse<sup>1</sup>, R.J. Bennink<sup>2</sup>, S. van Eeden<sup>3</sup>, P.A. Baars<sup>4</sup>, M. Löwenberg<sup>1</sup>, C.Y. Ponsioen<sup>1</sup>, G.R. van den Brink<sup>1</sup>, G.R. D'Haens<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, <sup>2</sup>Dept of Nuclear Medicine, <sup>3</sup>Dept of Pathology, and <sup>4</sup>Dept of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands*
- 13.50      Comparative efficacies of novel JAK inhibitors to reduce macrophage activation (p. 118)  
*L.C.S. de Vries<sup>1,2</sup>, J.M. Duarte<sup>1</sup>, F.W.M. Hilbers<sup>1</sup>, V.J. Ludbrook<sup>3</sup>, M.D. Woodrow<sup>3</sup>, M.J. Sims<sup>3</sup>, M. de Winther<sup>4</sup>, P.D. Moerland<sup>5</sup>, G.R.A.M. D'Haens<sup>2</sup>, W.J. de Jonge<sup>1,2</sup>, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, and <sup>2</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands, <sup>3</sup>Kinase DPU, GlaxoSmithKline, Stevenage, United Kingdom, <sup>4</sup>Dept of Medical Biochemistry, and <sup>5</sup>Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands*
- 14.00      Intestinal Epstein- Barr virus is associated with mucosal lymphoproliferation and subsequent intestinal surgery in inflammatory bowel disease patients (p. 119)  
*L.H.C. Nissen<sup>1</sup>, D.J. de Jong<sup>1</sup>, I.D. Nagtegaal<sup>2</sup>, W. Kievit<sup>1</sup>, L.A.A.P. Derikx<sup>1</sup>, M.G. Lynch<sup>2</sup>, F. Hoentjen<sup>1</sup>, J.H.J.M. van Krieken<sup>2</sup>, <sup>1</sup>Inflammatory Bowel Disease Center, Dept of Gastroenterology and Hepatology, and <sup>2</sup>Dept of Pathology, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands*
- 14.10      Predicting mucosal inflammatory activity in Crohn's disease: a new, validated nonendoscopic disease activity index (p. 120)  
*I.M. Minderhoud<sup>1</sup>, E.W. Steyerberg<sup>2</sup>, A.A. van Bodegraven<sup>3</sup>, C.J. van der Woude<sup>4</sup>, D.W. Hommes<sup>5</sup>, G. Dijkstra<sup>6</sup>, H.H. Fidder<sup>7</sup>, M.P. Schwartz<sup>8</sup>, B. Oldenburg<sup>7</sup>, <sup>1</sup>Dept of Internal Medicine and Gastroenterology, Tergooi Hospital, Hilversum, <sup>2</sup>Center for Medical Decision Making, Dept of Public Health, Erasmus MC, Rotterdam, <sup>3</sup>Dept of Gastroenterology, VU Medical Center, Amsterdam, <sup>4</sup>Dept of Gastroenterology, Erasmus MC, Rotterdam, The Netherlands, <sup>5</sup>Center for Inflammatory Bowel Diseases, UCLA Health System, Los Angeles, CA, USA, <sup>6</sup>Dept of Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, <sup>7</sup>Dept of Gastroenterology, University Medical Center Utrecht, Utrecht, <sup>8</sup>Dept of Gastroenterology, Meander Medical Center, Amersfoort, The Netherlands*
- 14.20      Only one third of Crohn's disease patients have sustained remission of perianal fistulas (p. 121)  
*I. Molendijk<sup>1</sup>, V.J.A.A. Nuij<sup>2</sup>, A.E. van der Meulen-de Jong<sup>1</sup>, C.J. van der Woude<sup>2</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>2</sup>Dept of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands*
- 14.30      Self-reported disability index in inflammatory bowel disease: results from a large Dutch prospective cohort (p. 122)  
*M. van der Have<sup>1</sup>, H.H. Fidder<sup>1</sup>, M. Leenders<sup>1</sup>, A.A. Kaptein<sup>2</sup>, M.E. van der Valk<sup>1</sup>, A.A. van Bodegraven<sup>3,12</sup>, G. Dijkstra<sup>4,5</sup>, D.J. de Jong<sup>6</sup>, M. Pierik<sup>7</sup>, C.Y. Ponsioen<sup>8</sup>, A.E. van der Meulen-de Jong<sup>9</sup>, C.J. van der Woude<sup>10</sup>, P.C. van de Meeberg<sup>11</sup>, M.J.L. Romberg-Camps<sup>12</sup>, C.H.M. Clemens<sup>13</sup>, J.M. Jansen<sup>14</sup>, N. Mahmod<sup>15</sup>, C.J.M. Bolwerk<sup>16</sup>, J.R. Vermeijden<sup>17</sup>, P.D. Siersema<sup>1</sup>, B. Oldenburg<sup>1</sup>, On behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis, <sup>1</sup>Dept of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, <sup>2</sup>Section Medical Psychology, Leiden, University Medical Center, <sup>3</sup>Dept of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, <sup>4</sup>Dept of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, <sup>5</sup>University of Groningen, Groningen, <sup>6</sup>Dept of Gastroenterology and Hepatology, Radboud*

Donderdag 20 maart 2014

University, Nijmegen Medical Center, Nijmegen, <sup>7</sup>Dept of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, <sup>8</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, <sup>9</sup>Dept of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>10</sup>Dept of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, <sup>11</sup>Dept of Gastroenterology and Hepatology, Slingeland Hospital, Doetinchem, <sup>12</sup>Dept of Gastroenterology and Hepatology, Orbis Medical Center, Sittard, <sup>13</sup>Dept of Gastroenterology and Hepatology, Diaconessenhuis, Leiden, <sup>14</sup>Dept of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, <sup>15</sup>Dept of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, <sup>16</sup>Dept of Gastroenterology and Hepatology, Reinier de Graaf Groep, Delft, <sup>17</sup>Dept of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, The Netherlands

14.40 The relevance of population based IBD biobanks: a meta-analysis and introduction of the IBD-SL biobank cohort (p. 123)

T.R.A. van den Heuvel<sup>1,2</sup>, D.M.A.E. Jonkers<sup>1,2</sup>, S.F.G. Jeuring<sup>1,2</sup>, W.H. Hameeteman<sup>1</sup>, L.E. Oostenbrug<sup>3</sup>, M.J.L. Romberg-Camps<sup>4</sup>, A.A.M. Masclee<sup>1,2</sup>, M.P. Zeegers<sup>5,6</sup>, M.J. Pierik<sup>1,2</sup>, <sup>1</sup>Dept of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, <sup>2</sup>Maastricht University Medical Center, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht, <sup>3</sup>Dept of Internal Medicine, Atrium Medical Center, Heerlen, <sup>4</sup>Dept of Internal Medicine, Orbis Medical Center, Sittard-Geleen, The Netherlands, <sup>5</sup>Dept of Public Health, Epidemiology and Biostatistics, University Hospital Birmingham, Birmingham, United Kingdom, <sup>6</sup>Dept of Complex Genetics, Cluster of Genetics and Cell Biology, Maastricht University Medical Center, Maastricht, The Netherlands

14.50 Is elderly-onset ulcerative colitis a different entity? Natural disease course and treatment response compared to adult-onset disease in a Dutch population-based cohort (p. 124)

S.F.G. Jeuring<sup>1,2</sup>, T.R.A. van den Heuvel<sup>1,2</sup>, M.P. Zeegers<sup>3,4</sup>, W.H. Hameeteman<sup>1</sup>, M.J.L. Romberg-Camps<sup>5</sup>, L.E. Oostenbrug<sup>6</sup>, A.A.M. Masclee<sup>1,2</sup>, D.M.A.E. Jonkers<sup>1,2</sup>, M.J. Pierik<sup>1,2</sup>, <sup>1</sup>Dept of Internal Medicine, Division of Gastroenterology and Hepatology, <sup>2</sup>NUTRIM, School for Nutrition, Toxicology and Metabolism, and <sup>3</sup>Dept of Complex Genetics, Cluster of Genetics and Cell Biology, Maastricht University Medical Center, Maastricht, The Netherlands, <sup>4</sup>Dept of Epidemiology and Public Health, University of Birmingham, Birmingham, United Kingdom, <sup>5</sup>Dept of Internal Medicine and Gastroenterology, Orbis Medical Center, Sittard, <sup>6</sup>Dept of Internal Medicine and Gastroenterology, Atrium Medical Center, Heerlen, The Netherlands

15.00 Theepauze expositiehal

Donderdag 20 maart 2014

---

**Minisymposium: Update Voeding in de dagelijkse praktijk**

---

**Parkzaal**

**Voorzitters:** J.P.H. Drenth en S.W.M. Olde Damink

- 15.30      Is voeding bij functionele aandoeningen zinvol?  
*Dr. L.A. van der Waaij, MDL-arts, Martini Ziekenhuis Groningen*
- 15.50      Voeding bij IBD: wat kunnen we van de kinderartsen leren?  
*Dr. A. Kindermann, kinderarts, Emma Kinderziekenhuis, Amsterdam*
- 16.10      Voedselintoleranties en allergieën: wat is dat eigenlijk?  
*Dr. T. Rustemeyer, dermatoloog, VU medisch centrum, Amsterdam*
- 16.30      Is er voldoende aandacht voor voeding bij klinische patiënten?  
*I.A. Meynaar, internist, HagaZiekenhuis, Den Haag*
- 16.50      Einde programma
- 17.00      Voor de uitreiking van de Frieda den Hartog Jager prijs met aansluitende  
lezing door  
prof. dr. J.H. Kleibeuker kunt u zich begeven naar de Brabantzaal

---

|                                                               |                    |
|---------------------------------------------------------------|--------------------|
| <b>Vrije voordrachten Sectie Gastrointestinale Endoscopie</b> | <b>Brabantzaal</b> |
|---------------------------------------------------------------|--------------------|

---

08.00 Ledenvergadering NVMDL

**Voorzitters:** M.A.M.J. Jacobs en Y.C.A. Keulemans

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

09.30 Risk of colorectal cancer after endoscopic vs. surgical resection of carcinoma in situ is not different (p. 125)

*K. Kessels<sup>1</sup>, L.M.G. Moons<sup>1</sup>, M.G.H. van Oijen<sup>1</sup>, P.D. Siersema<sup>1</sup>, M.A.G. Elferink<sup>2</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, <sup>2</sup>Comprehensive Cancer Center the Netherlands (IKNL), Utrecht, The Netherlands*

09.40 Endoscopic transpapillary gallbladder drainage in high-risk patients: the use of a double pigtail stent (p. 126)

*N. Boogerd<sup>1</sup>, L.E. Perk<sup>1</sup>, G.J.D. van Acker<sup>1</sup>, <sup>1</sup>Medical Center Haaglanden, Den Haag / Leidschendam, The Netherlands*

09.50 EUS-guided drainage with a large diameter metal stent is a safe treatment for acute cholecystitis in high risk patients (p. 127)

*D. Walter<sup>1</sup>, A.Y.B. Teoh<sup>2</sup>, T. Ito<sup>3</sup>, M. Pérez-Miranda<sup>4</sup>, A. Larghi<sup>5</sup>, A. Sanchez-Yague<sup>6</sup>, P. Vilmann<sup>7</sup>, P.D. Siersema<sup>1</sup>, F.P. Vleggaar<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, University Medical Center Utrecht, The Netherlands, <sup>2</sup>Dept of Surgery, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China, <sup>3</sup>Dept of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan, <sup>4</sup>Dept of Gastroenterology, Unit of Gastrointestinal Endoscopy, University Hospital Rio Hortega, Valladolid, Spain, <sup>5</sup>Digestive Endoscopy Unit, Catholic University, Rome, Italy, <sup>6</sup>Dept of Digestive Diseases, Endoscopy Unit, Agencia Sanitaria Costa del Sol, Marbella, Spain, <sup>7</sup>Dept of Endoscopy, Gastrointestinal Unit, Copenhagen University Hospital, Herlev, Denmark*

10.00 Hydraulic dilation in idiopathic achalasia using the EsoFLIP dilation balloon: a prospective cohort study (p. 128)

*W.F.W. Kappelle<sup>1</sup>, A. Bogte<sup>1</sup>, P.D. Siersema<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands*

10.10 Predictors for treatment failure after endoluminal fundoplication in GERD (p. 129)

*F.G. Smeets<sup>1</sup>, N.D. Bouvy<sup>2</sup>, A.A.M. Masclee<sup>1</sup>, J.M. Conchillo<sup>1</sup>, <sup>1</sup>Division of Gastroenterology and Hepatology, and <sup>2</sup>Dept of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands*

10.20 Are the gastric folds still the optimal landmark for defining the distal border of a Barrett's esophagus in a Western population? (p. 130)

*D. Schölvinck<sup>1,2</sup>, O. Goto<sup>3</sup>, K. Seldenrijk<sup>4</sup>, J. Bergman<sup>2</sup>, N. Yahagi<sup>3</sup>, B. Weusten<sup>1,2</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, <sup>2</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands, <sup>3</sup>Division of research and development for minimally invasive treatment, Cancer Center Keio University, Tokyo, Japan, <sup>4</sup>Dept of Pathology, St. Antonius Hospital, Nieuwegein, The Netherlands*

Vrijdag 21 maart 2014

10.30 Cost-effectiveness analysis of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF) (p. 131)

*K.N. Phoa<sup>1</sup>, W.D. Rosmolen<sup>1</sup>, B.L.A.M. Weusten<sup>1,2</sup>, R. Bisschops<sup>3</sup>, E.J. Schoon<sup>4</sup>, K. Ragunath<sup>5</sup>, G. Fullarton<sup>6</sup>, M. DiPietro<sup>7</sup>, N. Ravi<sup>8</sup>, M. Visser<sup>1</sup>, G.J. Offerhaus<sup>1</sup>, C.A. Seldenrijk<sup>2</sup>, S.L. Meijer<sup>1</sup>, F.J. ten Kate<sup>1</sup>, J.G.P. Tijssen<sup>1</sup>, M.G. Dijkgraaf<sup>1</sup>, J.J. Bergman<sup>1</sup>, <sup>1</sup>Academic Medical Center, University of Amsterdam, Amsterdam, <sup>2</sup>St. Antonius Hospital, Nieuwegein, The Netherlands, <sup>3</sup>UZ Gasthuisberg, Leuven, Belgium, <sup>4</sup>Catharina Hospital, Eindhoven, The Netherlands, <sup>5</sup>Queens Medical Centre, Nottingham, UK, <sup>6</sup>Royal Infirmary, Glasgow, <sup>7</sup>Addenbrookes Hospital, Cambridge, UK, <sup>8</sup>St James Hospital, Dublin, Ireland*

10.40 Efficacy and safety of HALO90-RFA-ablation using the simple protocol (3x15J-no cleaning) (p. 132)

*H.T. Künzli<sup>1,2</sup>, E.J. Schoon<sup>3</sup>, M.H. Houben<sup>4</sup>, J.J.G.H.M. Bergman<sup>2</sup>, B.L.A.M. Weusten<sup>1,2</sup>, <sup>1</sup>Dept of Gastroenterology, St. Antonius Hospital, Nieuwegein, <sup>2</sup>Academic Medical Center, Amsterdam, <sup>3</sup>Catharina Hospital, Eindhoven, <sup>4</sup>HaGa Hospital, The Hague, The Netherlands*

10.50 Detection of buried Barrett glands after Radiofrequency Ablation (RFA) with Volumetric Laser Endomicroscopy (VLE) (p. 133)

*A. Swager<sup>1</sup>, D.F. Boerwinkel<sup>1</sup>, D.M. de Bruin<sup>2</sup>, D.J. Faber<sup>2</sup>, T.G. van Leeuwen<sup>2</sup>, B.L. Weusten<sup>1</sup>, S.L. Meijer<sup>3</sup>, J.J. Bergman<sup>1</sup>, W.L. Curvers<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, <sup>2</sup>Dept of Biomedical Engineering, and <sup>3</sup>Dept of Pathology, Academic Medical Center, Amsterdam, The Netherlands*

11.00 Koffiepauze

---

**Sectie Gastrointestinale Endoscopie**

---

**Brabantzaal**

**Voorzitters:** J.W. Poley en B.L.A.M. Weusten

**PERK studie**

- 11.30      Kwaliteit van ERCP in Nederland - de PERK studie  
*V.E. Ekkelenkamp, namens de PERK studiegroep*
- 11.45      Discussie
- 11.50      “Meten is weten; ERCP kwaliteitsregistratie in Nederland”  
*Dr. M. Ledeboer, MDL-arts en voorzitter Commissie Kwaliteit NVMDL  
en A.D. Koch, MDL-arts, Erasmus MC, Rotterdam*
- 12.05      Discussie
- 12.15      Einde programma Perk studie

---

**Sectie Gastrointestinale Endoscopie**

---

**Brabantzaal**

**Voorzitters:** J.W. Poley en B.L.A.M. Weusten

**Richtlijn Antistolling**

- 12.15      Indicaties voor antitrombotische therapie  
*Dr. M. Brouwer, cardioloog, Radboud universitair medisch centrum,  
Nijmegen*
- 12.30      Werking en dosering van antitrombotische therapie  
*A. Prins, apotheker*
- 12.45      Achtergrond en bespreking herziende richtlijn Antitrombotische therapie en  
endoscopische procedures  
*Dr. F.T.M. Peters en Dr. M.E. Tushuizen, MDL-artsen*
- 13.00      Lunchbuffet in de expositiehal

Vrijdag 21 maart 2014

---

**Symposium Sectie Gastrointestinale Oncologie**

**Brabantzaal**

---

**Voorzitters:** A. Cats en J.M. van Dieren

**CRC bevolkingsonderzoek**

- 14.00 Inleiding  
*Dr. A. Cats, MDL-arts, Antoni van Leeuwenhoekhuis, Amsterdam*
- 14.10 Serrated polyposis syndroom - is herkenning belangrijk?  
*Prof. dr. E. Dekker, MDL-arts, Academisch Medisch Centrum, Amsterdam*
- 14.30 CRC - 1 ziekte?  
*Dr. L. Vermeulen, Center for Experimental Molecular Medicine (CEMM)  
Academisch Medisch Centrum & Cancer Research UK - Cambridge  
Institute*
- 14.50 Erfelijke darmkanker - new kids in town  
*Dr. M. Kets, klinisch geneticus, Radboudumc, Nijmegen*
- 15.10 Poliepectomie: state-of-the-art  
*Dr. S. Sanduleanu, MDL-arts, Maastricht Universitair Medisch Centrum*
- 15.30 Maligne colorectale poliepen  
*Dr. M.E. van Leerdam, MDL-arts, Antoni van Leeuwenhoekhuis,  
Amsterdam*

**Voorzitters:** E.J.M. van Geenen en M.I. van Berge Henegouwen

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

- 09.30 Predictive factors for recurrence of cryptoglandular perianal fistula characterised by pre-operative endoanal ultrasound (EAUS) (p. 134)  
*Visscher, A.P.<sup>1</sup>, Schuur, D.<sup>1</sup>, Deen, C.B.H.<sup>3</sup>, Van der Mijnsbrugge, G.J.H.<sup>3</sup>, Meijerink W.J.H.J.<sup>2</sup>, Felt-Bersma R.J.F.<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands, <sup>2</sup>Dept of Surgery, VU University Medical Center, Amsterdam, the Netherlands, <sup>3</sup>Proctos Kliniek, Bilthoven, the Netherlands*
- 09.40 Long term outcome after surgery for cryptoglandular perianal fistula (p. 135)  
*Van Nunspeet L.<sup>1</sup>, Sprakel J.<sup>2</sup>, Eddes E.H.<sup>1</sup>, Bosker R.J.I.<sup>1</sup>, de Noo M.E.<sup>1</sup>, <sup>1</sup>Dept of Surgery, Deventer Hospital, Deventer, The Netherlands, <sup>2</sup>Dept of Surgery, Martini Hospital, Groningen, The Netherlands*
- 09.50 Treatment response of EATL patients; a ten year analysis of a national cohort (p. 136)  
*P. Nijeboer<sup>1</sup>\*, L. de Baaij<sup>1</sup>\*, O. Visser<sup>2</sup>, C.J.J Mulder<sup>1</sup>, S.A.G.M. Cillessen<sup>3</sup>, G.Bouma<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology, VU University Medical Center, Amsterdam, the Netherlands, <sup>2</sup>Dept of Haematology, VU University Medical Center, Amsterdam, the Netherlands, <sup>3</sup>Dept of Pathology, VU University Medical Center, Amsterdam, the Netherlands, \*Both authors contributed equally to this article*
- 10.00 Surgery for complicated celiac disease (p. 137)  
*J.M.W. van de Water<sup>a</sup>, P. Nijeboer<sup>a</sup>, J. Zegers<sup>a</sup>, W.J.H.J. Meijerink<sup>b</sup>, C.J.J. Mulder<sup>a</sup>, D.L. van der Peet<sup>b</sup>, <sup>a</sup> Dept of Gastroenterology and <sup>b</sup> Dept of Surgery, VU University Medical Center, Amsterdam, The Netherlands*
- 10.10 Smooth muscle protein 22 (SM22) in plasma and urine reflects transmural ischemic injury of the intestines (p. 138)  
*D.H.S.M. Schellekens<sup>1-2</sup>, K.W. Reisinger<sup>1-2</sup>, J.P.M. Derikx<sup>1-2</sup>, K. Lenaerts<sup>1-2</sup>, W.A. Buurman<sup>2</sup>, C.H.C. Dejong<sup>1-2</sup>, <sup>1</sup>Dept of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands, <sup>2</sup> NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands*
- 10.20 Development of a prediction model to assess the risk of chronic gastrointestinal ischemia in referred patients (p. 139)  
*J. Hark<sup>1</sup>, Y. Vergouwe<sup>2</sup>, J.A. Spoor<sup>1</sup>, E.J. Kuipers<sup>1,3</sup>, P. B. Mensink<sup>1,4</sup>, M.J. Bruno<sup>1</sup>, D. van Noord<sup>1</sup>, E.T.T.L. Tjwa<sup>1,5</sup>, <sup>1</sup>Depts. of <sup>1</sup>Gastroenterology and Hepatology, <sup>2</sup>Public Health and <sup>3</sup>Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands, <sup>4</sup>Dept of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, The Netherlands, <sup>5</sup>Dept of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands*

Vrijdag 21 maart 2014

- 10.30 Does inclusion of imaging in the work up of patients with clinically suspected appendicitis reduce the rate of unnecessary surgical procedures? (p. 140)  
*K.W.A. Gottgens<sup>1</sup>, M.J. Lahaye<sup>2</sup>, D.M.J. Lambregts<sup>2</sup>, E. Mutsaers<sup>2</sup>, B. Essers<sup>3</sup>, N. Bouvy<sup>1</sup>, S.O. Breukink<sup>1</sup>, R.G.H. Beets-Tan<sup>2</sup>, <sup>1</sup>Dept of surgery, Maastricht University Medical Center, Maastricht, The Netherlands <sup>2</sup>Dept of radiology, Maastricht University Medical Center, Maastricht, The Netherlands <sup>3</sup>Dept of clinical epidemiology and medical technology assessment, Maastricht University Medical Center, Maastricht, The Netherlands*
- 10.40 Prognostication of complications after Roux en Y gastric bypass: evaluation of the OS-MRS and the Clavien-Dindo classification (p. 141)  
*U.K. Coblijn<sup>1</sup>, S.M.M. de Castro<sup>1</sup>, S.M. Lagarde<sup>2</sup>, W.F. van Tets<sup>1</sup>, L.Th. de Wit<sup>1</sup>, B.A. van Wagenveld<sup>1</sup>, <sup>1</sup>Sint Lucas Andreas Ziekenhuis, Dept of General Surgery<sup>2</sup> Academic Medical Center Amsterdam, Dept of General Surgery*
- 10.50 Peroral endoscopic myotomy for achalasia is safe and effective: a prospective single center study (p. 142)  
*F.A.M. Ponds<sup>1</sup>, T. Verlaan<sup>1</sup>, A.J.P.M. Smout<sup>1</sup>, A.J. Bredenoord<sup>1</sup>, P. Fockens<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology & Hepatology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.*
- 11.00 Koffiepauze

---

**Voordrachten Nederlandse Vereniging voor Gastroenterologie**

**Auditorium**

---

**Voorzitters:** A.J. Bredenoord en J.Ph. Kuijvenhoven

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

- 11.30 Esophageal epithelial barrier function in GERD patients and healthy controls: an ex-vivo study in the basal state and in response to acid exposure (p. 143)  
*N.F. Rinsma<sup>1</sup>, M. Elizalde<sup>1</sup>, F.J. Troost<sup>1</sup>, A.A. Masclee<sup>1</sup>, J.M. Conchillo<sup>1</sup>, <sup>1</sup>Dept of Internal Medicine, div. of Gastroenterology-Hepatology, NUTRIM, Maastricht University Medical Center, Maastricht, The Netherlands*
- 11.40 Trends in distribution of diagnostic testing and treatment of hepatocellular carcinoma in the Netherlands between 2003-2011 (p. 144)  
*S. van Meer<sup>1</sup>, K.J. Erpecum<sup>1</sup>, G.H. Schrier<sup>2</sup>, C. Verhoef<sup>3</sup>, J. Verheij<sup>4</sup>, R.A. de Man<sup>5</sup>, L.G.M. van der Geest<sup>2</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, University Medical Center, Utrecht, The Netherlands. <sup>2</sup>Comprehensive Cancer Center The Netherlands. <sup>3</sup>Dept of Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands. <sup>4</sup>Dept of Pathology, Academic Medical Center, Amsterdam, The Netherlands. <sup>5</sup>Dept of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands.*

- 11.50 Gut permeability in IBS is site specific, subtype dependent and affected by confounding factors (p. 145)  
*Z. Mujagic<sup>1\*</sup>, S. Ludidi<sup>1\*</sup>, D. Keszthelyi<sup>1</sup>, M.A. Hesselink<sup>1</sup>, J.W. Kruimel<sup>1</sup>, K. Lenaerts<sup>2</sup>, N.M. anssen<sup>3</sup>, J.M. Conchillo<sup>1</sup>, D.M. Jonkers<sup>1</sup>, A.A. Masclee<sup>1</sup>, \*Both authors contributed equally, <sup>1</sup>Dept of Internal Medicine, Division of Gastroenterology and Hepatology, and <sup>2</sup>Dept of Surgery, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, <sup>3</sup>Dept of Internal Medicine, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, The Netherlands*
- 12.00 Insufficient incorporation of biological meshes after implantation in a clean surgical environment (p. 146)  
*I.M. Mulder<sup>1</sup>, EB. Deerenberg<sup>1</sup>, W.A. Bemelman<sup>2</sup>, J. Jeekel<sup>3</sup>, J.F. Lange<sup>1</sup>, <sup>1</sup>Dept of Surgery Erasmus MC Rotterdam, <sup>2</sup>Dept of Surgery Amsterdam Medical Centre Amsterdam, <sup>3</sup>Dept of Neuroscience Erasmus MC Rotterdam, The Netherlands*
- 12.10 Distal versus proximal colonic acetate infusions differentially affect human metabolism (p. 147)  
*C. M. van der Beek<sup>\*1,2</sup>, E. E. Canfora<sup>\*1,3</sup>, K. Lenaerts<sup>1,2</sup>, F. J. Troost<sup>1,4</sup>, A.A.M. Masclee<sup>1,4</sup>, C. H.C. Dejong<sup>1,2</sup>, E.E. Blaak<sup>1,3</sup>, \* Shared first author <sup>1</sup>Top Institute Food and Nutrition, Wageningen, the Netherlands, <sup>2</sup>Dept of Surgery, <sup>3</sup>Dept of Human Biology, and <sup>4</sup>Dept of Internal Medicine, division of Gastroenterology-Hepatology; NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University, the Netherlands*
- 12.20 Transnasal endoscopic nasoenteral feeding tube placement in routine clinical practice is associated with low success rates (p. 148)  
*T.K.J. Groenhof<sup>1</sup>, D. Walter<sup>1</sup>, E.M.H. Mathus-Vliegen<sup>2</sup>, P.J. van der Schaar<sup>3</sup>, F.P. Vleggaar<sup>1</sup>, L. Nagtzaam<sup>1</sup>, P.D. Siersema<sup>1</sup>, M.M.C. Hirdes<sup>1</sup>, J.F. Monkelbaan<sup>1</sup>, <sup>1</sup> Dept of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, <sup>2</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, <sup>3</sup> Dept of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein*
- 12.30 Excellent long-term survival after autologous stem-cell transplantation for RCDII (p. 149)  
*P.Nijeboer<sup>1</sup>, R.L.J v Wanrooij<sup>1</sup>, T. v Gils<sup>1</sup>, N.J. Wierdsma<sup>2</sup>, H.J. Bontkes<sup>3</sup>, C.J.J. Mulder<sup>1</sup>, G. Bouma<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology, <sup>2</sup>Dept of Nutrition and Dietetics, <sup>3</sup>Dept of Pathology VU University medical centre Amsterdam, The Netherlands*
- 12.40 Clinical impact of liquid-based or cell block preparation of residual material after analysis of cytological smears in endoscopic ultrasound-guided fine-needle aspiration (p. 150)  
*W.F.W. Kappelle, M.G.H. van Oijen, P.D. Siersema, F.P. Vleggaar, Dept of Gastroenterology and Hepatology, University Medical Center Utrecht*
- 12.50 Lean Six Sigma in health care; Applicability and implementation in a fast track multidisciplinary oncology clinic (p. 151)  
*Y.L. Basta<sup>1</sup>, K.M.A.J. Tytgat<sup>2</sup>, T. Rohof<sup>3</sup>, M.C. Monster<sup>4</sup>, P. Fockens<sup>2</sup>, J.H.G. Klinkenbijn<sup>1</sup> On behalf of the GIOCA group, <sup>1</sup>Chirurgie, AMC <sup>2</sup> MDL, AMC <sup>3</sup> Stafbureau, AMC <sup>4</sup> ING*
- 13.00 Lunchbuffet in de expositiehal

**Voorzitters:** H. Braat en C.H.C. Dejong

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

14.00 Inleiding sessie door de voorzitter

14.10 Quality of life after stent placement for palliation of common bile duct obstruction: a randomized controlled trial comparing plastic and metal stents (p. 152)

*D. Walter<sup>1</sup>, P.G.A. van Boeckel<sup>1</sup>, M.J. Groenen<sup>2</sup>, B.L.A.M. Weusten<sup>3</sup>, B.J. Witteman<sup>4</sup>, G. Tan<sup>5</sup>, M. Brink<sup>6</sup>, J. Nicolai<sup>7</sup>, A.C. Tan<sup>8</sup>, J. Alderliesten<sup>9</sup>, N.G. Venneman<sup>10</sup>, W. Laleman<sup>11</sup>, J.M. Jansen<sup>12</sup>, A. Bodelier<sup>13</sup>, F.L. Wolters<sup>14</sup>, L.A. van der Waaij<sup>15</sup>, R. Breumelhof<sup>16</sup>, F.T.M. Peters<sup>17</sup>, R.C.H. Scheffer<sup>18</sup>, M. Leenders<sup>1</sup>, M.M.C. Hirdes<sup>1</sup>, F.P. Vleggaar<sup>1</sup>, P.D. Siersema<sup>1</sup>, <sup>1</sup>UMC Utrecht, Utrecht, Netherlands <sup>2</sup>Rijnstate Hospital, Arnhem, Netherlands <sup>3</sup>St. Antonius Hospital, Nieuwegein, Netherlands <sup>4</sup>Gelderse Vallei Hospital, Ede, Netherlands <sup>5</sup>Ziekenhuisgroep Twente Hospital, Hengelo, Netherlands <sup>6</sup>Meander Medical Center, Amersfoort, Netherlands <sup>7</sup>Haga Hospital, Den Haag, Netherlands <sup>8</sup>Canisius Wilhelmina Hospital, Nijmegen, Netherlands <sup>9</sup>Albert Schweitzer Hospital, Dordrecht, Netherlands <sup>10</sup>Medisch Spectrum Twente, Enschede, Netherlands <sup>11</sup>University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium <sup>12</sup>Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands <sup>13</sup>Amphia Hospital, Breda, Netherlands <sup>14</sup>VieCuri Hospital, Venlo, Netherlands, <sup>15</sup>Martini Hospital, Groningen, Netherlands <sup>16</sup>Diakonessen Hospital, Utrecht, Netherlands <sup>17</sup>UMCG, Groningen, Netherlands <sup>18</sup>Jeroen Bosch Hospital, Den Bosch, Netherlands*

14.20 Positive predictive value of endoscopic ultrasound (EUS) for the detection of intraluminal filling defects in the common bile duct (CBD) in a large non-academic teaching hospital (p. 153)

*L.M.J.W. van Driel<sup>1</sup>, R. Quispel<sup>1</sup>, B. Veldt<sup>1,2</sup>, M. Bruno<sup>2</sup>, <sup>1</sup>Reinier de Graaf hospital, Delft. <sup>2</sup>Erasmus Medical Center, Rotterdam*

14.30 A comparative prospective blinded analysis of the effectiveness of EUS and MRI as screening tools for pancreatic cancer (p. 154)

*F. Harinck<sup>1\*</sup>, I.C.A.W. Konings<sup>1\*</sup>, J.W. Poley<sup>1</sup>, N.C. Krak<sup>2</sup>, K. Biermann<sup>3</sup>, J.E. van Hooft<sup>4</sup>, C.Y. Nio<sup>5</sup>, C.M. Aalfs<sup>6</sup>, A. van Rens<sup>7</sup>, C. van Eijck<sup>8</sup>, D. Gouma<sup>9</sup>, M.G.W. Dijkgraaf<sup>10</sup>, H. van Dullemen<sup>11</sup>, R. Sijmons<sup>12</sup>, P. Fockens<sup>4</sup>, M.J. Bruno<sup>1</sup>, on behalf of the Dutch research group on pancreatic cancer surveillance in high-risk individuals, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, <sup>2</sup>Dept of Radiology, Erasmus MC, University Medical Center Rotterdam, <sup>3</sup>Dept of Pathology, Erasmus MC, University Medical Center Rotterdam, <sup>4</sup>Dept of Gastroenterology and Hepatology, Amsterdam Medical Center, University Medical Center Amsterdam, <sup>5</sup>Dept of Radiology, Amsterdam Medical Center, University Medical Center Amsterdam, <sup>6</sup>Dept of Clinical Genetics, Amsterdam Medical Center, University Medical Center Amsterdam, <sup>7</sup>Family Cancer Clinic, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, <sup>8</sup>Dept of Surgery, Erasmus MC, University Medical Center Rotterdam, <sup>9</sup>Dept of Surgery, Amsterdam Medical Center, University Medical Center Amsterdam, <sup>10</sup>Clinical Research Unit, Amsterdam Medical Center, University Medical Center Amsterdam, <sup>11</sup>Dept of Gastroenterology and Hepatology, University Medical Center Groningen, <sup>12</sup>Dept of Clinical Genetics, University Medical Center Groningen. \* contributed equally to this work*

- 14.40 CEA and cytopathological analysis are useful tests to discriminate mucinous from non-mucinous pancreatic cystic lesions (p. 155)  
*A. van de Vreede<sup>1</sup>, W.K. Utomo<sup>1</sup>, M.J. Bruno<sup>1</sup>, B.E. Hansen<sup>1</sup>, H. Braat<sup>1</sup>, K. Biermann<sup>2</sup>, <sup>1</sup> Dept of gastroenterology and hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands, <sup>2</sup> Dept of pathology Erasmus MC University Medical Centre, Rotterdam, The Netherlands*
- 14.50 Serous cystadenoma; a single center experience (p. 156)  
*J. Fest, J. Poley, M. Bruno en H. Braat, Erasmus MC, Rotterdam, The Netherlands*
- 15.00 Diagnostic value of a pancreatic mass on computed tomography in patients undergoing pancreatoduodenectomy for presumed pancreatic cancer (p. 157)  
*A. Gerritsen<sup>1,2</sup>, T.L. Bollen<sup>3</sup>, C.Y. Nio<sup>4</sup>, I.Q. Molenaar<sup>1</sup>, M.G. Dijkgraaf<sup>5</sup>, H.C. van Santvoort<sup>1</sup>, G.J. Offerhaus<sup>6</sup>, E.Sieders<sup>7</sup>, K.P. de Jong<sup>7</sup>, R.M. van Dam<sup>8</sup>, E. van der Harst<sup>9</sup>, H. van Goor<sup>10</sup>, B. van Ramshorst<sup>11</sup>, B.A. Bonsing<sup>12</sup>, I.H. de Hingh<sup>13</sup>, M.F. Gerhards<sup>14</sup>, C.H. van Eijck<sup>15</sup>, D.J. Gouma<sup>2</sup>, I.H. Borel Rinkes<sup>1</sup>, O.R. Busch<sup>2</sup>, and M.G. Besselink<sup>2</sup>, for the Dutch Pancreatic Cancer Group, <sup>1</sup>Dept of Surgery, University Medical Center Utrecht, <sup>2</sup>Dept of Surgery, Academic Medical Center Amsterdam, <sup>3</sup>Dept of Radiology, St. Antonius hospital Nieuwegein, <sup>4</sup>Dept of Radiology, Academic Medical Center Amsterdam, <sup>5</sup>Clinical Research Unit, Academic Medical Center Amsterdam, <sup>6</sup>Dept of Pathology, University Medical Center Utrecht, <sup>7</sup>Dept of Surgery, University Medical Center Groningen, <sup>8</sup>Dept of Surgery, Maastricht University Medical Center, <sup>9</sup>Dept of Surgery, Maasstad Ziekenhuis Rotterdam, <sup>10</sup>Dept of Surgery, Radboud University Medical Centre Nijmegen, <sup>11</sup>Dept of Surgery, St. Antonius hospital Nieuwegein, <sup>12</sup>Dept of Surgery, Leiden University Medical Center, <sup>13</sup>Dept of Surgery, Catharina hospital Eindhoven, <sup>14</sup>Dept of Surgery, OLVG Amsterdam, <sup>15</sup> Dept of Surgery, Erasmus Medical Center Rotterdam*
- 15.10 Comparison of Incidence Rates of Acute Pancreatitis and Pancreatic Cancer among the general population and type 2 Diabetes Mellitus patients between different Databases in the SAFEGUARD project (p. 158)  
*G.M.C. Masclee<sup>1</sup>, I.A. Leal<sup>1</sup>, P. Rijnbeek<sup>1</sup>, G. Trifiro<sup>1,10</sup>, G. De Berardis<sup>2</sup>, I. Bezemer<sup>3</sup>, M. Gil<sup>4</sup>, E. Martin<sup>4</sup>, G. Requena<sup>5</sup>, C. Sammon<sup>6</sup>, S. Pecchioli<sup>10</sup>, N. Schmedt<sup>7</sup>, T. Schink<sup>7</sup>, J.D. Seeger<sup>8</sup>, L. Scotti<sup>9</sup>, M. Pladevall<sup>1</sup>, M. Smits<sup>12</sup>, M.C.J.M. Sturkenboom<sup>1</sup>, S. Romio<sup>1,9</sup>, <sup>1</sup>Dept of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands, <sup>2</sup>Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy, <sup>3</sup> PHARMO Institute, Utrecht, Netherlands, <sup>4</sup>Spanish Agency for Drugs and Medical Devices, Madrid, Spain, <sup>5</sup> Pharmacology Unit, Dept of Biomedical Sciences II, University of Alcalá, Madrid, Spain, <sup>6</sup> University of Bath, Bath, United Kingdom, <sup>7</sup>Leibniz-Institute for Prevention Research and Epidemiology – BIPS GmbH, Bremen, Germany, <sup>8</sup>The Brigham and Women's Hospital, Harvard Medical School, Boston, United States, <sup>9</sup> University Milano-Bicocca, Milan, Italy, <sup>10</sup> Health Search, Italian College of General Practitioners, Florence, Italy, <sup>11</sup>RTI Health Solutions, Barcelona, Spain, <sup>12</sup>VU University Medical Center, Amsterdam, Netherlands*
- 15.20 Introduction of laparoscopic minor liver surgery in a HPB unit: not necessarily associated with a "learning curve" (p. 159)  
*F. Huisman<sup>1</sup>, M. J. Van der Poel<sup>1</sup>, M.G.H. Besselink<sup>1</sup>, P.J. Tanis<sup>1</sup>, T.M. van Gulik<sup>1</sup>, O.R.C. Busch<sup>1</sup>, <sup>1</sup> Dept of Surgery, Academic Medical Center, Amsterdam, The Netherlands*
- 15.30 Einde programma

Vrijdag 21 maart 2014

---

**Symposium Nederlandse Vereniging voor Hepatologie**

**Baroniezaal**

---

**Voorzitters:** U.H.W. Beuers en H.R. van Buuren

**"Cholestatische en virale leverziekten - een internationaal perspectief"**

- 09.30 PBC: wat hebben onze patiënten en wij geleerd van de 'PBC supergroep'?  
*Dr. H.R. van Buuren, MDL-arts, Erasmus MC, Rotterdam*
- 09.50 PSC: welke rol hebben genetica voor het ontstaan en de voortgang van PSC?  
*Prof. dr. R. Weersma, MDL-arts, UMC Groningen*
- 10.10 IAC: is IgG4-gerelateerde ziekte van galwegen en pancreas een beroepsziekte?  
*Prof. dr. U.H.W. Beuers, MDL-arts, Academisch Medisch Centrum, Amsterdam*
- 10.30 Inleiding hepatologie in Europa  
*Prof. dr. R.J. Oude Elferink, biochemicus, Tytgat Instituut, AMC, Amsterdam*
- 10.35 De Nederlandse Hepatologie - een Europees perspectief  
*Prof. dr. P.L.M. Jansen, MDL-arts, AMC Amsterdam, Maastricht UMC*
- 10.45 Inleiding virale hepatitis  
*Prof. dr. J.P.H. Drenth, MDL-arts, Radboudumc, Nijmegen*
- 10.50 De virale hepatitis zorg in Nederland - gisteren, vandaag, morgen  
*Prof. dr. S.W. Schalm, MDL-arts, Erasmus MC Rotterdam*
- 11.00 Einde programma

**Theme Immunology and IBD – Chairs: G. Bouma and D.M.A.E. Jonkers**

**09.00** De postersessie van de DEGH vindt plaats tussen 09.00 en 11.00 uur. Vanaf 09.00 uur zullen alle posters worden gepresenteerd in een plenaire sessie met behulp van een powerpoint slide. Na het presenteren van de posters zal er gelegenheid zijn tot het stellen van vragen bij de desbetreffende posters. In de zaal is een ontbijtbuffet aanwezig.

- 1.** Sympathetic rather than vagal activity modulates acute DSS colitis in mice  
*C. Cailotto<sup>1</sup>, B.J. Olivier<sup>1</sup>, L. Costes<sup>1</sup>, J. van der Vliet<sup>1</sup>, F. Hilbers<sup>1</sup>, W.J. de Jonge<sup>1</sup>, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, The Netherlands*
- 2.** Prediction of response to adalimumab induction therapy in Crohn's disease patients  
*C.P. Peters<sup>1,2</sup>, F.H. van Dooren<sup>1</sup>, N.W. Duijvis<sup>1</sup>, S.C. Wolfkamp<sup>1</sup>, E.W. Vogels<sup>1</sup>, C. Verseijden<sup>1</sup>, S. Meisner<sup>1</sup>, P.C. F. Stokkers<sup>3</sup>, P.D. Moerland<sup>4</sup>, C.Y. Ponsioen<sup>2</sup>, A.A. te Velde<sup>1</sup>, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, <sup>2</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, <sup>3</sup>Dept of Gastroenterology and Hepatology, St Lucas Andreas Hospital, Amsterdam, <sup>4</sup>Dept of Clinical Epidemiology, Biostatistics and Bioinformatics, Bioinformatics Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands*
- 3.** Potential mechanisms of therapeutic cannabis use in chronic pancreatitis  
*W.K. Utomo<sup>1</sup>, K. Parikh<sup>2</sup>, M. de Vries<sup>3</sup>, H. van Goor<sup>3</sup>, M.J. Bruno<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, H. Braat<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, <sup>2</sup>Dept of Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, <sup>3</sup>Dept of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands*
- 4.** Longitudinal analysis of TRAIL and CD158b expression on peripheral and intrahepatic NK cells in HCV patients during triple therapy  
*M. Spaan<sup>1</sup>, R.A. de Groen<sup>1</sup>, G.W. van Oord<sup>1</sup>, H.L.A. Janssen<sup>1,2</sup>, R.J. de Knecht<sup>1</sup>, A. Boonstra<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, <sup>2</sup>Liver Clinic University Health Network, Division of Gastroenterology, University of Toronto, Canada*
- 5.** Analysis of the transcriptome and immune function of monocytes during IFN $\alpha$ -based therapy in chronic HCV infection revealed induction of TLR7 responsiveness  
*J. Hou<sup>1</sup>, Z.M. Groothuisink<sup>1</sup>, L. Koning<sup>1</sup>, R. Roomer<sup>1</sup>, W. van IJcken<sup>2</sup>, K. Kreeft<sup>1</sup>, B. Liu<sup>1</sup>, H.L.A. Janssen<sup>1,3</sup>, R.J. de Knecht<sup>1</sup>, A. Boonstra<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, and <sup>2</sup>Center for Biomics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, <sup>3</sup>Liver Clinic University Health Network, Division of Gastroenterology, University of Toronto, Canada*

Vrijdag 21 maart 2014

6. **Rapamycin and everolimus facilitate hepatitis e virus replication: reveal an antiviral function of PI3K-AKT-mTOR pathway**  
*X. Zhou<sup>1</sup>, Y. Wang<sup>1</sup>, H.L.A. Janssen<sup>1,2</sup>, H.J. Metselaar<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, Q. Pan<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, <sup>2</sup>Division of Gastroenterology, University Health Network, Toronto, Canada*
7. **T cell characteristics during acute hepatitis B virus infection**  
*S.B. Willemse<sup>1,2</sup>, A. de Niet<sup>1,2</sup>, F. Stelma<sup>1,2</sup>, M.J. Tempelmans Plat-Sinnige<sup>2</sup>, E.B.M. Remmerswaal<sup>2</sup>, H.W. Reesink<sup>1</sup>, E.M.M. van Leeuwen<sup>2</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, and <sup>2</sup>Dept of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands*
8. **The number of human commensal bacterium *Faecalibacterium prausnitzii* is significantly increased in the fecal samples of patients with active Crohn's disease**  
*E. Caljouw<sup>1</sup>, M.R.K.L. Lie<sup>1</sup>, M. Elizabeth<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, C.J. van der Woude<sup>1</sup>, S.R. Konstantinov<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands*
9. **Bacterial translocation to the pancreas revealed after analyses of the pancreatic cyst fluids**  
*V. Narayanan<sup>1</sup>, W.K. Utomo<sup>1</sup>, M.J. Bruno<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, H. Braat<sup>1</sup>, S.R. Konstantinov<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands*
10. **Expression and localization of IL-21 in the gastrointestinal mucosa of pediatric Crohn's Disease patients**  
*L.M.M. Costes<sup>1</sup>, D.J. Lindenberg-Kortleve<sup>1</sup>, M.A. van Leeuwen<sup>1</sup>, S. Veenbergen<sup>1</sup>, C.I. de Bie<sup>1</sup>, J.C. Escher<sup>1</sup>, L. de Ridder<sup>1</sup>, J.N. Samsom<sup>1</sup>, <sup>1</sup>Dept of Pediatric Gastroenterology, Erasmus MC, Sophia Children's Hospital, Rotterdam, The Netherlands*
11. **Overexpression of Cyp27a1 in hematopoietic cells reduces hepatic inflammation independently of 27-hydroxycholesterol levels in plasma and liver**  
*T. Hendriks, M.L.J. Jeurissen<sup>1</sup>, V. Bieghs<sup>1</sup>, S.M.A. Walenbergh<sup>1</sup>, P.J. van Gorp<sup>1</sup>, F. Verheyen<sup>1</sup>, T. Houben<sup>1</sup>, Y. Dias Guichot<sup>1</sup>, M.J.J. Gijbels<sup>1</sup>, G.H. Koek<sup>1</sup>, E. Leitersdorf<sup>2</sup>, M.H. Hofker<sup>3</sup>, D. Lütjohann<sup>4</sup>, R. Shiri-Sverdlov<sup>1</sup>, <sup>1</sup>Depts of Molecular Genetics, Molecular Cell Biology, Electron Microscopy, Pathology and Internal Medicine; Nutrition and Toxicology Research (NUTRIM) and Cardiovascular Research (CARIM) Institutes of Maastricht, University of Maastricht, Maastricht, The Netherlands, <sup>2</sup>Dept of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, <sup>3</sup>Dept of Pathology and Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, <sup>4</sup>Institute of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn, Germany*
12. **Characterization and quantification of human dendritic cell subsets in healthy and diseased livers**  
*E. van der Aa<sup>1</sup>, P.J. Biesta<sup>1</sup>, F. Ayhan<sup>1</sup>, H.L.A. Janssen<sup>1</sup>, A.M. Woltman<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands*

**Theme**      **Metabolism and therapy – Chairs: A.A. te Velde and R.K. Weersma**

09.00      De postersessie van de DEGH vindt plaats tussen 09.00 en 11.00 uur. Vanaf 09.00 uur zullen alle posters worden gepresenteerd in een plenaire sessie met behulp van een powerpoint slide. Na het presenteren van de posters zal er gelegenheid zijn tot het stellen van vragen bij de desbetreffende posters. In de zaal is een ontbijtbuffet aanwezig.

1.      **LGR5+ liver organoids as a model to study polycystic liver disease**  
*E.S. Wills<sup>1,2</sup>, R. te Morsche<sup>1</sup>, R. Roepman<sup>2,3</sup>, J.H. de Wilt<sup>4</sup>, M. Huch<sup>5</sup>, H. Clevers<sup>5</sup>, J.P.H. Drenth<sup>1</sup>, <sup>1</sup>Dept of Medicine, Division of Gastroenterology and Hepatology, <sup>2</sup>Dept of Human Genetics, <sup>3</sup>Nijmegen Center for Molecular Life Sciences, and <sup>4</sup>Dept of Surgery, Radboud University Medical Center, Nijmegen, <sup>5</sup>Hubrecht Institute for Developmental Biology and Stem Cell Research, University Medical Center Utrecht, Utrecht, The Netherlands*
  
2.      **MicroRNAs to assess warm ischemic injury during machine perfusion of liver grafts from circulatory death donors**  
*C.J. Verhoeven<sup>1</sup>, D. Monbaliu<sup>2</sup>, I. Habib<sup>1</sup>, J. de Jonge<sup>1</sup>, T. Wylin<sup>2</sup>, I. Jochmans<sup>2</sup>, V. Heedfeld<sup>2</sup>, Metselaar<sup>1</sup>, J. Kwekkeboom<sup>1</sup>, R.W.F. de Bruin<sup>1</sup>, G. Kazemier<sup>3</sup>, J. IJzermans<sup>1</sup>, J. Pirenne<sup>2</sup>, L.J.W. van der Laan<sup>1</sup>, <sup>1</sup>Dept of Surgery and Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands, <sup>2</sup>Dept of Abdominal Transplant Surgery, University Hospitals/ KU Leuven, Belgium, <sup>3</sup>Dept of Surgery, VU Medical Center, Amsterdam, The Netherlands*
  
3.      **Increased expression efficiency by codon optimization for viral gene therapy of Crigler-Najjar syndrome**  
*R. van Dijk<sup>1</sup>, N. van Til<sup>2</sup>, C. Riviere<sup>3</sup>, S. Duijst<sup>1</sup>, D.R. de Waart<sup>1</sup>, U. Beuers<sup>1,4</sup>, P.J. Bosma<sup>1</sup>, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, University of Amsterdam, Amsterdam, <sup>2</sup>Dept of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands, <sup>3</sup>Genethon, Evry, France, <sup>4</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands*
  
4.      **Secretory leukocyte protease inhibitor (SLPI) is a potent regulator of small intestinal myeloid cell driven tolerance**  
*C.L. Menckeborg<sup>1</sup>, Y. Simons-Oosterhuis<sup>1</sup>, D.J. Lindenbergh-Kortleve<sup>1</sup>, L. de Ruiter<sup>1</sup>, H.C. Raatgeep<sup>1</sup>, L.A. van Berkel<sup>1</sup>, P.E. van Lierop<sup>2</sup>, E.E.S. Nieuwenhuis<sup>2</sup>, L. de Ridder<sup>3</sup>, J.C. Escher<sup>3</sup>, J.N. Samsom<sup>1</sup>, <sup>1</sup>Laboratory of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus MC, Rotterdam, <sup>2</sup>Wilhelmina Children's Hospital, Utrecht, <sup>3</sup>Dept of Pediatric Gastroenterology, Sophia Children's Hospital, Rotterdam, The Netherlands*
  
5.      **Co-administration of 5-aminosalicylic acid to 6-mercaptopurine reduces in vitro hepatotoxicity in HepaRG cells**  
*M.M.T.J. Broekman<sup>1</sup>, H.M.J. Roelofs<sup>1</sup>, M. Kerstholt<sup>1</sup>, F. Hoentjen<sup>1</sup>, W.H.M. Peters<sup>1</sup>, G.J.A. Wanten<sup>1</sup>, D.J. de Jong<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands*

Vrijdag 21 maart 2014

6. **High throughput compound library screen to identify selective FXR agonists for inflammatory bowel disease**  
*I.T.G.W. Bijsmans<sup>1</sup>, D. Lelieveld<sup>2</sup>, D.A. Egan<sup>2</sup>, S.W.C. van Mil<sup>1</sup>, <sup>1</sup>Molecular Cancer Research, Section Metabolic Diseases, and <sup>2</sup>Cell Screening Center, Dept of Cell Biology, University Medical Center Utrecht, Utrecht, The Netherlands*
7. **In vitro pancreas toxicity by azathioprine but not 6-mercaptopurine**  
*M.M.T.J. Broekman<sup>1</sup>, H.M.J. Roelofs<sup>1</sup>, T. Demir<sup>1</sup>, F. Hoentjen<sup>1</sup>, W.H.M. Peters<sup>1</sup>, G.J.A. Wanten<sup>1</sup>, D.J. de Jong<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands*
8. **IMPDH2-targeted constraint of cell growth in hepatocellular carcinoma by mycophenolic acid**  
*K. Chen<sup>1,2</sup>, K. Man<sup>3</sup>, H.J. Metselaar<sup>1</sup>, H.L.A. Janssen<sup>1,4</sup>, J. Kwekkeboom<sup>1</sup>, D. Sprengers<sup>1</sup>, M.J. Bruno<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, Q. Pan<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, <sup>2</sup>Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China, <sup>3</sup>Dept of Surgery, the Hong Kong University, Hong Kong, <sup>4</sup>Division of Gastroenterology, University Health Network, Toronto, Canada*
9. **Ophthalmate levels following paracetamol challenge during hepatectomy: a translational model of liver function**  
*K. van Mierlo<sup>1</sup>, S.A.W.G. Dello<sup>1</sup>, M.C. de Jong<sup>1</sup>, H.M.H. van Eijk<sup>1</sup>, T.M. de Kok<sup>3</sup>, J.J. Briedé<sup>3</sup>, S.W.M. Olde Damink<sup>1,2</sup>, C.H.C. Dejong<sup>1</sup>, <sup>1</sup>Dept of Surgery, Maastricht University Medical Center and Nutrim School for Nutrition, Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands, <sup>2</sup>Dept of Surgery, University College London Hospitals and University College London, Division of Surgery and Interventional Science, London, United Kingdom, <sup>3</sup>Dept of Health Risk Analysis and Toxicology, Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands*
10. **Qualitative comparison between two mouse hepatocyte culture systems for bile salt signalling studies**  
*E.H. Gilgioni<sup>1,2</sup>, I.C. Gaemers<sup>1</sup>, R.P.J. Oude Elferink<sup>1</sup>, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, The Netherlands, <sup>2</sup>Dept of Physiological Science, State University of Maringá, Brazil*
11. **Melatonin suppresses the activation of hepatic stellate cells**  
*S. Shajari<sup>1</sup>, L. Almudena<sup>1</sup>, H. Moshage<sup>1</sup>, K.N. Faber<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands*
12. **Efficacy of absorbable embolization materials for portal vein embolization to induce liver regeneration in a rabbit model**  
*F. Huisman<sup>1</sup>, K.P. van Lienden<sup>2</sup>, J. Verheij<sup>3</sup>, T.M. van Gulik<sup>1</sup>, <sup>1</sup>Dept of Surgery, <sup>2</sup>Dept of Radiology, and <sup>3</sup>Dept of Pathology, Academic Medical Center, Amsterdam, The Netherlands*
13. **Intestinal FXR is essential in the hepatic growth response to prolonged cholic acid exposure**  
*M. Doktorova<sup>1</sup>, F.A.J.A. Bodewes<sup>1</sup>, H.J. Verkade<sup>1</sup>, J.W. Jonker<sup>1</sup>, <sup>1</sup>Center for Liver, Digestive and Metabolic Diseases, Dept of Pediatrics, University Medical Center Groningen, Groningen, The Netherlands*

---

**DEGH oral presentations**

**Baroniezaal**

---

**Voorzitters:** K.K. Krishnadath en P.D. Siersema

- 11.30 Translational science teaching Session: Barrett's Esophagus  
Clinical aspects: *prof. dr. P.D. Siersema, MDL-arts, UMC Utrecht*
- 11.55 Translational/basic science aspects: *prof. dr. K.K. Krishnadath, MDL-arts, AMC, Amsterdam*

Voordrachten in het Engels, spreektijd 8 minuten, discussietijd 4 minuten

- 12.20 Overexpression of HOXA13 in Barrett's esophagus is a potential mediator of its posterior phenotype (p. 160)  
*V.T. Janmaat<sup>1</sup>, A.P. Verhaar<sup>1</sup>, M.J. Bruno<sup>1</sup>, M.P. Peppelenbosch<sup>1</sup>, M.C.W. Spaander<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands*
- 12.32 Comprehensive profiling of plasma microRNAs reveals potential biomarkers for Barrett's esophagus and esophageal adenocarcinoma (p. 161)  
*J.W.P.M. van Baal<sup>1</sup>, P. Bus<sup>1</sup>, C. Kestens<sup>1</sup>, F.J.W. ten Kate<sup>2</sup>, W.H.M. Peters<sup>3</sup>, J.P.H. Drenth<sup>3</sup>, J.M. Roodhart<sup>4</sup>, E.E. Voest<sup>4</sup>, P.D. Siersema<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, and <sup>2</sup>Dept of Pathology, University Medical Center Utrecht, Utrecht, <sup>3</sup>Dept of Gastroenterology, Radboud University Medical Center, Nijmegen, <sup>4</sup>Dept of Medical Oncology, University Medical Center Utrecht, Utrecht The Netherlands*
- 12.45 Lunchbuffet in de expositiehal

---

**DEGH oral presentations**

**Baroniezaal**

---

**Voorzitters:** G. Dijkstra en P.C.F. Stokkers

- 14.00 Translational Science Teaching Session: Inflammatory Bowel Disease  
Clinical aspects: *Dr. P.C.F. Stokkers, MDL-arts, St. Lucas Andreas Ziekenhuis*
- 14.24 Translational/Basic science aspects: *Prof. dr. G. Dijkstra, MDL-arts, UMC Groningen*

Vrijdag 21 maart 2014

Voordrachten in het Engels, spreektijd 8 minuten, discussietijd 4 minuten

- 14.48      Trans-ethnic association study of IBD identifies 14 new disease loci and demonstrates pervasive sharing of genetic risk factors and phenotypic features between Europeans and Non-Europeans (p. 162)  
*S. van Sommeren<sup>1,2\*</sup>, J.Z. Liu<sup>3\*</sup>, A. Takahashi<sup>4</sup>, J.C. Lee<sup>5</sup>, B.K. Thelma<sup>6</sup>, R. Malekzadeh<sup>7</sup>, J.C. Barrett<sup>3</sup>, J.H. Cheon<sup>8</sup>, H. Huang<sup>9</sup>, A. Franke<sup>10</sup>, International IBD Genetics Consortium, M. Parkes<sup>5</sup>, A.P. Morris<sup>11</sup>, B.Z. Alizadeh<sup>12</sup>, S.C. Ng<sup>13</sup>, C.A. Anderson<sup>3</sup>, M. Kubo<sup>14</sup>, R.K. Weersma<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, and <sup>2</sup>Dept of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, <sup>3</sup> Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK, <sup>4</sup>Laboratory for Statistical Analysis, Center for Genomic Medicine, RIKEN, Yokohama, Japan, <sup>5</sup>Inflammatory Bowel Disease Research Group, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK, <sup>6</sup>Dept of Genetics, University of Delhi South Campus, New Delhi, India, <sup>7</sup>Digestive Diseases Research Institute, Shariati Hospital, Tehran, Iran, <sup>8</sup>Dept of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea, <sup>9</sup>Analytic and Translational Genetics Unit, Dept of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, <sup>10</sup>Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany, <sup>11</sup>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK, <sup>12</sup>Dept of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, <sup>13</sup>Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong, <sup>14</sup>Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN, Yokohama, Japan*
- 15.00      Interleukin-10 inhibits human IFN $\gamma$ -secreting effector T cells indirectly by controlling antigen-presenting cell function (p. 163)  
*S. Veenbergen<sup>1</sup>, M.A. van Leeuwen<sup>1</sup>, G.J. Driessen<sup>2</sup>, L.F. de Ruiter<sup>1</sup>, H.C. Raatgeep<sup>1</sup>, D.J. Lindenberg-Kortleve<sup>1</sup>, Y. Simons-Oosterhuis<sup>1</sup>, L. de Ridder<sup>1</sup>, J.C. Escher<sup>1</sup>, J.N. Samsom<sup>1</sup>, <sup>1</sup>Dept of Pediatric Gastroenterology, Erasmus MC, Sophia Children's Hospital, Rotterdam, <sup>2</sup>Dept of Pediatric Infectious Disease and Immunology, Erasmus MC, Rotterdam, The Netherlands*
- 15.12      The role of microRNA-142-5P in experimental colitis (p. 164)  
*C. Kunne<sup>1</sup>, M.M.W. Slaman<sup>1</sup>, F.H. van Dooren<sup>1</sup>, S.L. Meijer<sup>2</sup>, K. Fluiter<sup>3</sup>, E.W. Vogels<sup>1</sup>, P.D. Moerland<sup>4</sup>, A.A. te Velde<sup>1</sup>, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, <sup>2</sup>Dept of Pathology, <sup>3</sup>Dept of Neurogenetics, and <sup>4</sup>Dept of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands*
- 15.24      Identification of novel non-transcriptionally acting glucocorticoid receptor ligands that suppress T cell activation but lack adipogenic activity (p. 165)  
*A.P. Verhaar<sup>1,2</sup>, R. Dvorsky<sup>3</sup>, M.E. Wildenberg<sup>2</sup>, M. Löwenberg<sup>2</sup>, M.P. Peppelenbosch<sup>4</sup>, D.W. Hommes<sup>1,5\*</sup>, G.R. van den Brink<sup>2\*</sup>, <sup>\*</sup>Both authors contributed equally, <sup>1</sup>Dept of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>2</sup>Tytgat Institute for Liver and Intestinal Research and Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands, <sup>3</sup>Max Planck Institute of Molecular Physiology, Dortmund, Germany, <sup>4</sup>Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, <sup>5</sup>Center for Inflammatory Bowel Diseases, University of California Los Angeles, Los Angeles, USA*
- 15.36      Differential induction of dendritic cell-mediated T cell tolerance in the small and large intestine (p. 166)  
*S. Veenbergen<sup>1</sup>, M.F. du Pré<sup>1</sup>, L.A. van Berkel<sup>1</sup>, F. Luk<sup>1</sup>, Y. Simons-Oosterhuis<sup>1</sup>, J.N. Samsom<sup>1</sup>, <sup>1</sup>Dept of Pediatric Gastroenterology, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands*

Vrijdag 21 maart 2014

15.48      Efficacy of a novel JAK1-specific inhibitor in a mouse model of acute and chronic colitis (p. 167)

*J. Duarte<sup>1</sup>, L. de Vries<sup>1,4</sup>, F. Hilbers<sup>1</sup>, M. de Winther<sup>2</sup>, M. Sims<sup>3</sup>, V. Ludbrook<sup>3</sup>, M. Woodrow<sup>3</sup>, J. Witherington<sup>3</sup>, G. D'Haens<sup>4</sup>, W.J. de Jonge<sup>1,4</sup>, <sup>1</sup>Tytgat Institute for Liver and Intestinal Research, and <sup>2</sup>Dept of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands, <sup>3</sup>Kinase DPU, GlaxoSmithKline, Stevenage, UK, <sup>4</sup>Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands*

16.00      **Abstract and Poster prizes**

16.10      Einde programma

Vrijdag 21 maart 2014

---

**Voordrachten Ned. Vereniging voor Gastroenterologie en Sectie IBD**

**Parkzaal**

---

**Voorzitters:** J.J. Keller en J.J. Kolkman

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

**09.30      Gluten degrading enzyme effectively digests gluten in the stomach and small intestine of healthy volunteers (p. 168)**

*B. Salden<sup>1\*</sup>, V. Monserrat<sup>3\*</sup>, F.J. Troost<sup>1</sup>, M.J. Bruins<sup>2</sup>, L. Edens<sup>2</sup>, R. Bartholomé<sup>4</sup>, B. Winkens<sup>5</sup>, F. Koning<sup>3</sup>, A. Masclee<sup>1</sup>, <sup>1</sup>Dept of Internal Medicine, division of Gastroenterology-Hepatology, NUTRIM, Maastricht University Medical Center, Maastricht, The Netherlands; <sup>2</sup> DSM Biotechnology Centre, Delft, The Netherlands; <sup>3</sup> Dept of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands; <sup>4</sup>Dept of Pharmacology and Toxicology, NUTRIM, University Maastricht, The Netherlands; <sup>5</sup>Dept of Methodology and Statistics, Maastricht University Medical Center, Maastricht, The Netherlands; \*these authors contributed equally to this work.*

**09.40      High frequency of concomitant immune-mediated diseases in celiac disease in a large Dutch cohort (p. 169)**

*Spijkerman M<sup>1</sup>, Visschedijk MC<sup>1,2</sup>, Withoff S<sup>2</sup>, Wijmenga C<sup>2</sup>, Kolkman JJ<sup>1,3</sup>, Weersma RK<sup>1</sup>, <sup>1</sup> University Medical Centre Groningen, Dept. of Gastroenterology and Hepatology, The Netherlands, <sup>2</sup>University Medical Centre Groningen, Dept. of Genetics, The Netherlands, <sup>3</sup> Medical Spectrum Twente, Dept. of Gastroenterology and Hepatology, The Netherlands.*

**09.50      Relapse rates of type 1 and 2 autoimmune pancreatitis: long-term outcome (p. 170)**

*J. Buijs<sup>1</sup>, D.L. Cahen<sup>1</sup>, M.J. van Heerde<sup>1</sup>, E.A. Rauws<sup>2</sup>, L.J. Maillette de Buij Wenniger<sup>2</sup>, B.E. Hansen<sup>1</sup>, K. Biermann<sup>1</sup>, J. Verheij<sup>2</sup>, F.P. Vleggaar<sup>3</sup>, M.A. Brink<sup>4</sup>, U.H.W. Beuers<sup>2</sup>, H.R. van Buuren<sup>1</sup>, M.J. Bruno<sup>1</sup>, <sup>1</sup> Erasmus University Medical Center, Rotterdam, The Netherlands <sup>2</sup> Academic Medical Center, Amsterdam, The Netherlands <sup>3</sup> University Medical Center Utrecht, The Netherlands <sup>4</sup> Meander Medical Center, Amersfoort, The Netherlands*

**10.00      Incidence of Microscopic Colitis in the Netherlands. A Nationwide Population-Based Study from 2000-2012 (p. 171)**

*B.P.M. Verhaegh<sup>1,2</sup>, D.M.A.E. Jonkers<sup>1,2</sup>, A.Driessen<sup>3</sup>, M.P. Zeegers<sup>2,4,5</sup>, A.A.M. Masclee<sup>1,2</sup>, M.J. Pierik<sup>1</sup>, <sup>1</sup> Division Gastroenterology-Hepatology, Dept of Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands <sup>2</sup> NUTRIM, School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center+, Maastricht, the Netherlands <sup>3</sup> Dept of Pathology; Maastricht University Medical Center+, Maastricht, the Netherlands <sup>4</sup> Dept of Complex Genetics, Cluster of Genetics and Cell Biology, Maastricht University Medical Center+, Maastricht, the Netherlands <sup>5</sup> Dept of Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham, United Kingdom*

**10.10      Immunoglobulin-bound bacteria in pediatric IBD patients (p. 172)**

*R.A.A.M. Govaarts<sup>1,2</sup>, D. Zaidi<sup>1,2</sup>, R. Valcheva<sup>2</sup>, Y. Lou<sup>1,2</sup>, C.J.J. Mulder<sup>4</sup>, L.A. Dieleman<sup>2,3</sup>, E. Wine<sup>1,2</sup>, <sup>1</sup>Division of Pediatric Gastroenterology, Dept of Pediatrics, University of Alberta, Edmonton, Alberta, Canada <sup>2</sup> Centre of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, Alberta, Canada <sup>3</sup> Division of Gastroenterology, Dept of Medicine, University of Alberta, Edmonton, Canada, <sup>4</sup>Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands*

- 10.20 Lower abundance of Uncultured Clostridiales in PSC patients (p. 173)  
*N.G.M. Rossen<sup>1</sup>, S. Fuentes<sup>2</sup>, K. Boonstra<sup>1</sup>, G. D'Haens<sup>1</sup>, H.G.H.J. Heilig<sup>2</sup>, E.G. Zoetendal<sup>2</sup>, W. M. de Vos<sup>2</sup>, C.Y. Ponsioen<sup>1,1</sup>*,<sup>1</sup> Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands. <sup>2</sup>Laboratory of Microbiology, Wageningen University, Wageningen, the Netherlands.
- 10.30 High Infliximab trough levels are associated with impaired quality of life in IBD patients in clinical and biochemical remission on maintenance IFX therapy (p. 174)  
*L.M.C. Vos, J.F. Brandse, C. Ponsioen, G. van den Brink, G.R.A.M. D'Haens, M. Löwenberg*, Academisch Medisch Centrum, Amsterdam, The Netherlands
- 10.40 Low dose naltrexone in therapy resistant IBD, a case series (p. 175)  
*M.R.K.L. Lie, G.M. Fuhler, A. de Lima, C. van der Ent, C.J. van der Woude*, Dept of Gastroenterology, Erasmus University Hospital, Rotterdam, The Netherlands
- 10.50 Interspace microbiome profiling (IS-pro) enables to differentiate IBD subclasses and disease activity by specific loss of bacterial diversity (p. 176)  
*M.E. Grasman<sup>1</sup>, R. van der Borden<sup>1, 2</sup>, A.E. Budding<sup>2</sup>, A. Eck Hauer<sup>2</sup>, P.H.M. Savelkoul<sup>2</sup>, A.A. van Bodegraven<sup>3</sup>*,<sup>1</sup>VU Medisch Centrum, afdeling Gastroenterologie en Hepatologie, <sup>2</sup>VU Medisch Centrum, afdeling Medische Microbiologie en Infectiepreventie, <sup>3</sup>ORBIS Medisch Centrum, afdeling Gastroenterologie en Hepatologie
- 11.00 Koffiepauze

---

**Vrije voordrachten Sectie Inflammatoire Darmziekten**

**Parkzaal**

---

**Voorzitters:** G. Dijkstra en R. West

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

- 11.30 Preconception care in IBD women leads to less disease relapses during pregnancy (p. 177)  
*A. de Lima<sup>1</sup>, Z. Zelinkova<sup>1,2</sup>, C. van der Ent<sup>1</sup>, C.J. van der Woude<sup>1</sup>*,<sup>1</sup> Erasmus Medical Center, Rotterdam, The Netherlands<sup>2</sup> University Hospital, Bratislava, Slovakia
- 11.40 Anti-TNF is safe to stop in the second trimester of pregnancy in IBD women in remission (p. 178)  
*A. de Lima<sup>1</sup>, Z. Zelinkova<sup>1,2</sup>, C. Van der Ent<sup>1</sup>, C.J. van der Woude<sup>1</sup>*,<sup>1</sup>Erasmus Medical Center, Rotterdam, The Netherlands<sup>2</sup> University Hospital, Bratislava, Slovakia

Vrijdag 21 maart 2014

- 11.50      **Decision-making, counselling and course of pregnancy in female inflammatory bowel disease patients (p. 179)**  
*J. Hoekstra<sup>1</sup>, J.E. Baars<sup>1</sup>, A.H.C. van Roon<sup>1</sup>, M. Kimmel<sup>1</sup>, M. Zwijnenburg<sup>2</sup>, F.C. Bekkering<sup>2</sup>, A.J.P. van Tilburg<sup>1</sup>, R.L. West<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, Sint Franciscus Gasthuis, Rotterdam, <sup>2</sup>Dept of Gastroenterology and Hepatology, IJsselland Hospital, Capelle aan de IJssel, The Netherlands*
- 12.00      **The Pharmacokinetics of Infliximab and Markers for Response to Induction Therapy in Patients with moderate to severe Ulcerative Colitis (p. 180)**  
*J.F. Brandse<sup>1</sup>, J.M. Jansen<sup>2</sup>, D. van der Kleij<sup>3</sup>, G.J. Wolbink<sup>3,4</sup>, I.M. Rigter<sup>5</sup>, P.A. Baars<sup>6</sup>, M. Löwenberg<sup>1</sup>, C.Y. Ponsioen<sup>1</sup>, G.R. van den Brink<sup>1</sup>, R.A. Mathôt<sup>6</sup>, G.R. D'Haens<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands <sup>2</sup>Dept of Gastroenterology, Onze Lieve Vrouwe Gasthuis, Amsterdam <sup>3</sup>Biologicals Laboratory, Sanquin Diagnostic Services, Amsterdam <sup>4</sup>Dept of Rheumatology, Jan van Bremen Research Institute, Reade, Amsterdam <sup>5</sup>Dept of Hospital Pharmacy, Academic Medical Center, Amsterdam <sup>6</sup>Dept of Experimental Immunology, Academic Medical Center, Amsterdam*
- 12.10      **Large variation in infliximab trough levels is associated with disease activity in pediatric Inflammatory Bowel Disease (p. 181)**  
*D.R. Hoekman<sup>1</sup>; J.F. Brandse<sup>2</sup>; T.G. de Meij<sup>3</sup>; T.Z. Hummel<sup>1</sup>; M. Lowenberg<sup>2</sup>; M.A. Benninga<sup>1</sup>; G.R.A.M. D'Haens<sup>2</sup>; A. Kindermann<sup>1</sup>, <sup>1</sup>Pediatric Gastroenterology and Nutrition, Academic Medical Center/Emma Children, Amsterdam, Netherlands. <sup>2</sup>Gastroenterology, Academic Medical Center, Amsterdam, Netherlands. <sup>3</sup>Pediatric Gastroenterology, VU University Medical Center, Amsterdam, Netherlands.*
- 12.20      **Top-down versus step-up treatment in newly diagnosed Crohn: no difference in long-term outcome (p. 182)**  
*J.A. Stibbe<sup>1</sup>; D.R. Hoekman<sup>1</sup>; F.J. Baert<sup>2</sup>; P. Caenepeel<sup>3</sup>; P. Vergauwe<sup>4</sup>; M. De Vos<sup>5</sup>; S.A. Vermeire<sup>3</sup>; G.R.A.M.S. D'Haens<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology, Academic Medical Center, Amsterdam, the Netherlands <sup>2</sup>Dept of Gastroenterology, AZ Delta, Roeselare, Belgium <sup>3</sup>Dept of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium <sup>4</sup>Dept of Gastroenterology, AZ Groeninge Hospital, Kortrijk, Belgium <sup>5</sup>Dept of Gastroenterology, Ghent University Hospital, Ghent, Belgium*
- 12.30      **Skewed thiopurine metabolism leads to early therapeutic failure in the majority of patients with inflammatory bowel disease (p. 183)**  
*Kreijne, J.E.<sup>1</sup>, M.L. Seinen, M.L.<sup>1</sup>, Sinjewel, A.<sup>2</sup>, Bouma, G.<sup>1</sup>, Mulder, C.J.<sup>1</sup>, van Bodegraven, A.A.<sup>1</sup> and de Boer, N.K.H.<sup>1</sup>, <sup>1</sup>VU University Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands <sup>2</sup>VU University Medical Center, Pharmacy Dept, Amsterdam, Netherlands*
- 12.40      **Early assessment of thiopurine metabolites predicts thiopurine-induced leukopenia in inflammatory bowel disease patients (p. 184)**  
*D.R. Wong<sup>1</sup>, M.J.H. Coenen<sup>2</sup>, L.J.J. Derijks<sup>3</sup>, C.J. van Marrewijk<sup>2</sup>, S.H. Vermeulen<sup>2,4</sup>, A.L.M. Verbeek<sup>4</sup>, B. Franke<sup>2,6</sup>, H-J. Guchelaar<sup>7</sup>, D.J. de Jong<sup>8</sup>, L.G.J.B. Engels<sup>9</sup>, P.M. Hooymans<sup>1</sup>; on behalf of the TOPIC study group., <sup>1</sup>Dept of Clinical Pharmacy and Toxicology, Orbis Medical Centre, Sittard-Geleen, The Netherlands; <sup>2</sup>Dept of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands; <sup>3</sup>Dept of Clinical Pharmacy, Máxima Medical Centre, Veldhoven, The Netherlands; <sup>4</sup>Dept for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands; <sup>5</sup>Dept of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, The Netherlands; <sup>6</sup>Dept of Psychiatry, Radboud University Medical Centre, Nijmegen, The Netherlands; <sup>7</sup>Dept of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands; <sup>8</sup>Dept of Gastroenterology, Radboud University Medical Centre, Nijmegen, The Netherlands; <sup>9</sup>Dept of Gastroenterology, Orbis Medical Centre, Sittard-Geleen; The Netherlands*

Vrijdag 21 maart 2014

- 12.50 FcR-mediated effector function contributes to the therapeutic response of anti-TNF monoclonal antibodies in a mouse model of IBD (p. 185)  
*A.D. Levin,<sup>1</sup> M.E. Wildenberg,<sup>1</sup> G.R.A.M. D'Haens,<sup>2</sup> and G.R. van den Brink.<sup>1,2</sup>,<sup>1</sup> Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, the Netherlands <sup>2</sup>Dept of Gastroenterology & Hepatology, Academic Medical Center, Amsterdam, the Netherlands*
- 13.00 Korte ledenvergadering Sectie Inflammatoire Darmziekten
- 13.15 Lunchbuffet in de expositiehal.

**Voorzitters:** C.F. Jonkers en G.J.A. Wanten

Voordrachten in het Nederlands, spreektijd 7 minuten, discussietijd 3 minuten

- 10.00      Interrater reliability of the Chicago Classification in pediatric high-resolution esophageal manometry recordings (p. 186)  
*M.J. Smits<sup>1</sup>, M.M.J. Singendonk<sup>1,2</sup>, I.E. Heijting<sup>a</sup>, M.P. van Wijk<sup>1</sup>, S. Nurko<sup>3</sup>, R. Rosen<sup>3</sup>, P.W. Wijenborg<sup>6</sup>, R. Abu-Assi<sup>2</sup>, D.R. Hoekman<sup>1</sup>, G. Seiboth<sup>2</sup>, M.A. Benninga<sup>1</sup>, T.I. Omari<sup>2,4,5</sup>, S. Kritis<sup>2</sup>, <sup>1</sup>Dept of Pediatric Gastroenterology and Nutrition, Emma Children's Hospital AMC, Amsterdam, The Netherlands; <sup>2</sup> Gastroenterology Unit, Women's and Children's Health Network, North Adelaide, Australia; <sup>3</sup>Center for Motility and Functional Gastrointestinal Disorders, Division of Gastroenterology, Children's Hospital Boston, Boston, USA; <sup>4</sup> School of Medicine, Flinders University, Bedford Park, South Australia; <sup>5</sup>Translational Research Center for Gastrointestinal Diseases, University of Leuven, Belgium; <sup>6</sup> Dept of Gastroenterology and Hepatology AMC, Amsterdam, The Netherlands*
- 10.10      The effect of oral vitamin B<sub>12</sub> supplementation on fatigue in patients with irritable bowel syndrome or inflammatory bowel disease (p. 187)  
*A.M. Scholten<sup>1</sup>, E. Vermeulen<sup>2</sup>, M. Koopmann<sup>3</sup>, T. Verhagen<sup>4</sup>, R.A. Dhonukshe-Rutten<sup>5</sup>, B.J.M. Witteman<sup>6</sup>, <sup>1</sup>Dept of Nutrition and Dietetics, Haagse Hogeschool, The Hague, <sup>2</sup>Dept of European Law, University of Groningen, <sup>3</sup> Dept of Clinical Pharmacy, Gelderse Vallei Hospital, Ede, <sup>4</sup>Dept of Nutrition, NCOI, Eindhoven, <sup>5</sup>Dept of Human Nutrition, Wageningen University, <sup>6</sup>Dept of Gastroenterology, Gelderse Vallei Hospital, Ede, The Netherlands*
- 10.20      Comprehensive nutritional status of patients with (refractory) coeliac disease and EATL at diagnosis (p. 188)  
*N.J. Wierdsma<sup>1</sup>, P. Nijeboer<sup>2</sup>, M.A.E. de van der Schueren<sup>1</sup>, G. Bouma<sup>2</sup>, A.A. van Bodegraven<sup>2</sup>, C.J.J. Mulder<sup>2</sup>, <sup>1</sup>Dept of Nutrition and Dietetics, and <sup>2</sup>Dept of Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands*
- 10.30      Taurine and major surgical trauma, role of the route of nutrition (p. 189)  
*F.F.B.M. Heesakkers<sup>1</sup>, P.G. Boelens<sup>3</sup>, M.D.P. Luyer<sup>1</sup>, K.W.Y. van Barneveld<sup>4</sup>, A.N. Roos<sup>2</sup>, J. Bakker, N.D. Bouvy<sup>4</sup>, H.J.T. Rutten<sup>1,5</sup>, <sup>1</sup>Dept of Surgery, and <sup>2</sup>Dept of Intensive Care Medicine, Catharina Hospital, Eindhoven, <sup>3</sup>Dept of Surgery, Leiden University Medical Center, Leiden, <sup>4</sup>Dept of Surgery, and <sup>5</sup>Research Institute Growth and Development, Maastricht University Medical Center, Maastricht, The Netherlands*
- 10.40      Unimpaired anabolic response to oral meal feeding in patients with pancreatic cancer cachexia (p. 190)  
*D.P.J. van Dijk<sup>1</sup>, M.C.G. van de Poll<sup>1,2</sup>, A.G.W. Moses<sup>3</sup>, T. Preston<sup>4</sup>, S.W.M. Olde Damink<sup>1</sup>, S.S. Rensen<sup>1</sup>, N.E.P. Deutz<sup>1</sup>, P.B. Soeters<sup>1</sup>, J.A. Ross<sup>3</sup>, K.C.H. Fearon<sup>3</sup>, C.H.C. Dejong<sup>1,3</sup>, <sup>1</sup>Dept of Surgery, Maastricht University Medical Center and NUTRIM School of Nutrition, Toxicology and Metabolism, Maastricht University, <sup>2</sup>Dept of Intensive Care Medicine, Maastricht University Medical Center, The Netherlands, <sup>3</sup>Dept of Surgery, Royal Infirmary of Edinburgh, Scotland, <sup>4</sup>Stable Isotope Biochemistry Laboratory, Scottish Universities Environmental Research Centre, East Kilbride, Glasgow, Scotland*

Vrijdag 21 maart 2014

10.50 Enteral glutamine administration increases urea production (p. 191)  
*M.C.G. van de Poll<sup>1,2</sup>, S.W.M. Olde Damink<sup>1</sup>, C.H.C. Dejong<sup>1</sup>, <sup>1</sup>Dept of Intensive Care Medicine, and <sup>2</sup>Dept of General Surgery, Maastricht University Medical Center, Maastricht, The Netherlands*

11.00 Koffiepauze

---

**Symposium NESPEN**

**Zaal 80**

---



### **Symposium 'klinisch voedingsonderzoek'**

**Voorzitters:** Dr. M. de van der Schueren, Lector HAN, research diëtist VUmc  
Dr. G. Wanten, gastroenteroloog Radboudumc

11.15 Introductie en doelstellingen symposium  
(Platform research dietitians and nurse practitioners)  
*Dr. M.A.E. de van der Schueren*

11.30 Sarcopenie, do's and don'ts met voeding bij ouderen  
*Prof. dr. ir. Marjolein Visser, hoogleraar 'Gezond ouder worden' aan het VUmc*

12.10 Discussie

### **Presentaties onderzoek: 7 minuten presenteren / 3 minuten discussie**

12.20 Rustmetabolisme van patiënten die in aanmerking komen voor een levertransplantatie in het LUMC  
*A. Donker en A. Droop, diëtisten LUMC*

12.30 Cross-culturele adaptatie van de Scored Patiënt-Generated Subjective Global Assessment (PG-SGA) naar de Nederlandse setting  
*M.J. Sealy, RD, BSc, Hanze Hogeschool Groningen*

- 12.40      Onderzoek naar de fysiologische bijwerkingen op de korte- en lange termijn bij kinderen met refractaire epilepsie behandeld met het ketogeen dieet  
*E.J.T.M van der Louw, RD, EMC/ Sophia Kinderziekenhuis*
- 12.50      Protein-enriched 'regular products' and their effect on protein intake in hospitalized older adults; a randomized controlled trial  
*S. Stelten, diëtist VUmc*
- 13.00      Validity of the "rate a plate" method to estimate energy and protein intake in hospitalized patients  
*I.M. Dekker diëtist, VUmc*
- 13.10      Proefschriftprijs presentatie
- 13.25      Uitreiking proefschriftprijs door voorzitter NESPEN
- 13.30      Wat hebben we vandaag geleerd ... waar willen we naartoe  
*C.F. Jonkers, RD, secretaris NESPEN*
- 13.30      Lunchbuffet in de expositiehal

---

**Programma V&VN MDL**

**Beneluxzaal**

---



- 10.10      Opening door de voorzitter
- 10.15      Barrett slokdarm, endoscopische detectie en behandeling  
vroegcarinomen  
*Mw. W. Rosmolen, MDL-arts i.o., AMC, Amsterdam*
- 10.40      Maagcarcinoom  
*Mw. J. van Dieren, MDL-arts, Antoni van Leeuwenhoek Zks, Amsterdam*
- 11.05      Behandeling van levermetastasen bij colorectaal carcinoom  
*Mw. H. Kleijwegt, verpleegkundig specialist, Zks Gelderse Vallei, Ede*
- 11.25      Behandeling van darmkanker met chemotherapie  
*Mw. S. de Bie, verpleegkundig specialist, Medisch Centrum Alkmaar*
- 11.45      Algemene ledenvergadering  
*Mw. T. Korpershoek, voorzitter V&VN Maag Darm Lever*
- 12.15      Lunchbuffet in de expositiehal

---

**Middagprogramma Endoscopieverpleegkundigen**

**Beneluxzaal**

---

**Voorzitter:** W. Kok

- 13.45      Endo-echo en MDL oncologie  
*Mw. A. Vehmeijer, MDL-arts, Kennemer Gasthuis, Haarlem*
- 14.15      Hoe gaat het verder na de scopie; operaties bij colorectaal carcinoom  
*Dhr. R. Smeenk, chirurg, Atrium MC, Heerlen*
- 14.45      ERCP bij maligniteit  
*Dhr. M. Tushuizen, MDL-arts, Amstelland Ziekenhuis, Amstelveen*
- 15.15      Einde programma


Vrijdag 21 maart 2014

---

**Middagprogramma Lever-/IBD verpleegkundigen**

---

**Zaal 63**



**Voorzitter:** N. Ipenburg

- 13.45      Hepatocellulair carcinoom  
*Dhr. K.J. van Erpecum, MDL-arts, UMC Utrecht*
- 14.15      IBD en extra-intestinale maligniteiten  
*Mw. L. Nissen, AIOS MDL, UMC St Radboud, Nijmegen*
- 14.45      Screening colorectaal carcinoom bij IBD  
*Dhr. B. Oldenburg, MDL-arts, UMC Utrecht*
- 15.15      Einde programma

---

**Programma Voedingsverpleegkundigen / MDL kliniek verpleegkundigen**      **Zaal 64**

---

**Voorzitter:** A. Pouwelsen

- 13.45      Parenterale voeding bij de oncologische patiënt  
*Mw. W. van Amsterdam, diëtist, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam*
- 14.15      Stomazorg na operatie voor colorectaal carcinoom  
*Mw. J. Boots, stomaverpleegkundige, Gelre Ziekenhuis, Apeldoorn*
- 14.45      Screening hereditair colorectaal carcinoom  
*Mw. M. van Vugt, IBD verpleegkundige, UMC St Radboud, Nijmegen*
- 15.15      Einde programma

## Smad4-dependent regulation of hepatocellular carcinoma growth and progression

*P.Y. Hernanda<sup>1</sup>, C. Kan<sup>1</sup>, A.M. Das<sup>2</sup>, K. Sideras<sup>1</sup>, S.J.A Bots<sup>1</sup>, H.L.A. Janssen<sup>1,3</sup>, L.L. Kodach<sup>4</sup>, H.J. Metselaar<sup>1</sup>, J.Kwekkeboom<sup>1</sup>, D. Sprengers<sup>1</sup>, M.J. Bruno<sup>1</sup>, T.L.M. ten Hagen<sup>2</sup>, M.P. Peppelenbosch<sup>1</sup>, Q.Pan<sup>1</sup>, <sup>1</sup>Dept of Gastroenterology and Hepatology, and <sup>2</sup>Laboratory of Experimental Surgical Oncology, Section Surgical Oncology, Dept of Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, <sup>3</sup>Division of Gastroenterology, University Health Network, Toronto, Canada, <sup>4</sup>Dept of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands*

SMAD4 is recognized as a central mediator of Transforming Growth Factor Beta (TGF- $\beta$ ) and Bone Morphogenetic Protein (BMP) signaling pathways which are involved in regulating tumor progression. In general, SMAD4 is considered a tumor suppressor. Here we investigated the role of SMAD4 in hepatocellular carcinoma (HCC). We performed immunohistochemical stainings in paraffin embedded-tissue microarray patient HCC (n=42). Three HCC cell lines were used for functional assay in vitro and in immune-deficient mice. The results were SMAD4 protein level was significantly higher in human HCC tissue compared with adjacent liver tissue (n=42,  $P < 0.05$ ). High SMAD4 levels were significantly associated with higher recurrence rate ( $p = 0.05$ ), shorter time to recurrence ( $p < 0.05$ ) and more tumor lesion ( $p < 0.01$ ). Interestingly, high SMAD4 levels were associated with low p-SMAD 1/5/8 (a downstream target of BMP signaling) expression, both in patients and HCC cell lines. Knockdown of SMAD4 in HCC cell lines showed a significant decrease of migratory and colony formation capacity, whereas ectopic overexpression of SMAD4 resulted in increased migration activity demonstrated by the ring-barrier migration assay. However, knockdown of SMAD4 conferred resistance to the anti-growth effects of BMP4, TGF- $\beta$  and Activin in HCC cell lines. Interim analysis (at day 12) of xenograft experiment showed that Smad4 knockdown appears to delay tumor initiation of HCC cells in nude mice.

Conclusion: Basal SMAD4 expression is required for the anti-tumor function of BMP signaling in HCC. Elevated Smad4 expression correlates with poor outcome in HCC patients and more aggressive phenotype and function of HCC cells.